Cisplatin
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | PLATINOL-AQ | — | 1981-12-29 – 1993-04-22 | fda.gov ↗ |
| Approved | US (FDA) | PLATINOL-AQ | — | 1978-12-19 | fda.gov ↗ |
Trials 2,253 · started per year
Also used as a comparator or background therapy in 1,864 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT07295262 Background | Jan 2026 → Jul 2028 expected | adult hepatocellular carcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT07168785 Background | Oct 2025 → Jun 2027 expected | head and neck squamous cell carcinoma | Indiana University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04161248 Background | Sep 2020 → Dec 2026 expected | B-cell non-Hodgkin lymphoma | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02550327 Background | Jan 2016 → Jun 2021 | pancreatic adenocarcinoma | Baylor Research Institute | Completed | No outcome recorded |
| Phase 0 | NCT00140556 Background | Aug 2005 → May 2009 | pharynx cancer | David M. Brizel, MD | Completed | No outcome recorded |
| Phase 1236 trials | ||||||
| Phase 1 | NCT07444710 Background | Aug 2026 → Sep 2027 expected | mantle cell lymphoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07697040 Background | Jul 2026 → Jul 2029 expected | esophageal squamous cell carcinoma | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07688252 Background | Jul 2026 → Dec 2032 expected | neuroblastoma | Chang Gung Memorial Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07699757 Background | Jul 2026 → Apr 2029 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07619313 Background | Jun 2026 → Jun 2027 expected | cholangiocarcinoma, pancreatic ductal adenocarcinoma | Jonsson Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Show all 236 trials opens the full record — a long page | ||||||
| Phase 1/2151 trials | ||||||
| Phase 1/2 | NCT06694454 Background | Jul 2026 → Dec 2031 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07632235 Comparator | Jul 2026 → Dec 2029 expected | intrahepatic cholangiocarcinoma | Shanghai 6th People's Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07392541 Background | Jan 2026 → Jan 2028 expected | biliary tract cancer | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07141771 Background | Dec 2025 → Jun 2030 expected | small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07261592 Background | Dec 2025 → Sep 2028 expected | urinary bladder cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting | No outcome recorded |
| Show all 151 trials opens the full record — a long page | ||||||
| Phase 2746 trials | ||||||
| Phase 2 | NCT04910386 Background | Jun 2027 → Jun 2029 expected | biliary tract neoplasm | 3D Medicines (Sichuan) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07369791 Background | Dec 2026 → Dec 2035 | biliary tract cancer | National Health Research Institutes, Taiwan | Withdrawn | No outcome recorded |
| Phase 2 | NCT07281417 Background | Nov 2026 → Dec 2030 expected | nasal cavity and paranasal sinus squamous cell carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT07332351 Background | Sep 2026 → Jan 2027 expected | infiltrating bladder urothelial carcinoma | University of Washington | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07649369 Comparator | Aug 2026 → Jan 2028 expected | pleural neoplasm | Shanghai Jeyou Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Show all 746 trials opens the full record — a long page | ||||||
| Phase 2/380 trials | ||||||
| Phase 2/3 | NCT07608224 Comparator | Jun 2026 → Jun 2030 expected | urinary bladder cancer | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07365319 Background | Jun 2026 → Dec 2035 expected | non-small cell lung carcinoma | Eikon Therapeutics | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07554456 Comparator | Jun 2026 → Dec 2028 expected | esophageal squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07642024 Comparator | Jun 2026 → Dec 2032 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07598318 Background | May 2026 → Dec 2027 expected | cholangiocarcinoma | Sir Run Run Shaw Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07662395 Background | May 2026 → Jan 2030 expected | — | Sinocelltech Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07063745 Comparator | Jan 2026 → Aug 2031 expected | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07251062 Comparator | Dec 2025 → Dec 2029 expected | esophageal squamous cell carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07332533 Background | Dec 2025 → Jun 2032 expected | carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07100080 Comparator | Nov 2025 → Dec 2028 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07106762 Comparator | Sep 2025 → Jan 2029 expected | urothelial carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07129993 Background | Sep 2025 → Jun 2029 expected | urinary bladder cancer, urothelial carcinoma | Daiichi Sankyo | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07005102 Background | Aug 2025 → Dec 2031 expected | non-small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07472153 Comparator | Jul 2025 → Jun 2030 expected | cervical cancer | N.N. Alexandrov National Cancer Centre | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06493552 Comparator | Mar 2025 → Sep 2029 expected | urinary bladder carcinoma, urothelial carcinoma | Vasgene Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06755515 Background | Sep 2024 → Sep 2028 expected | cervical cancer | Shandong New Time Pharmaceutical Co., LTD | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT06288373 Comparator | Apr 2024 → Mar 2031 expected | cervical cancer | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06236438 Background | Apr 2024 → Oct 2031 expected | non-small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07528495 Background | Apr 2024 → Dec 2027 expected | head and neck cancer | All India Institute of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06354530 Background | Mar 2024 → Dec 2025 overdue | esophageal squamous cell carcinoma | Army Medical Center of PLA | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06214572 Comparator | Mar 2024 → Jul 2029 expected | gallbladder cancer | Tata Memorial Centre | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06241599 Background | Feb 2024 → Feb 2026 overdue | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06123884 Background | Dec 2023 → Sep 2026 expected | cervical cancer | Bio-Thera Solutions | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05800015 Background | Aug 2023 → Jan 2030 expected | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05063552 Background | Mar 2023 → Dec 2027 expected | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, lip and oral cavity squamous cell carcinoma, nasal cavity and paranasal sinus squamous cell carcinoma +5 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05691478 Background | Mar 2023 → Mar 2030 expected | conventional osteosarcoma, localized osteosarcoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05489848 Comparator | Aug 2022 → Aug 2028 expected | endometrial cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05433597 Comparator | Jul 2022 → Jul 2024 overdue | nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05058651 Background | Jun 2022 → Oct 2028 | neuroendocrine carcinoma | National Cancer Institute (NCI) | Suspended | No outcome recorded |
| Phase 2/3 | NCT05213312 Background | Jun → Nov 2022 | esophageal squamous cell carcinoma | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT05576272 Background | May 2022 → Dec 2024 | nasopharyngeal carcinoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/3 | NCT05255302 Background | May 2022 → May 2025 overdue | non-small cell lung carcinoma | French Cooperative Thoracic Intergroup | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05057130 Background | Jan 2022 → Dec 2024 | bone sarcoma, connective and soft tissue neoplasm, osteosarcoma | Blokhin's Russian Cancer Research Center | Unknown | No outcome recorded |
| Phase 2/3 | NCT05255653 Background | Nov 2021 → Jan 2030 expected | endometrial cancer | Leiden University Medical Center | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05125055 Background | Oct 2021 → Sep 2024 overdue | oral cavity squamous cell carcinoma | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04702009 Background | Jan 2021 → Oct 2025 | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Completed | No outcome recorded |
| Phase 2/3 | NCT04619797 Background | Dec 2020 → Apr 2024 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2/3 | NCT04750083 Background | Sep 2020 → Sep 2022 | non-small cell lung carcinoma | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/3 | NCT04442022 Background | Sep 2020 → Dec 2026 expected | diffuse large B-cell lymphoma | Karyopharm Therapeutics Inc | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04066491 Background | Sep 2019 → May 2021 | cholangiocarcinoma, gallbladder cancer | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded |
| Phase 2/3 | NCT03992911 Comparator | Jun 2019 → Jun 2022 | neuroendocrine carcinoma | Peking University | Unknown | No outcome recorded |
| Phase 2/3 | NCT06105619 Comparator | Oct 2018 → Apr 2023 overdue | glioblastoma | Beijing Pearl Biotechnology Limited Liability Company | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03588494 Background | Aug 2018 → Sep 2019 | — | Affiliated Hospital of North Sichuan Medical College | Unknown | No outcome recorded |
| Phase 2/3 | NCT02923258 Comparator | Apr 2018 → Feb 2022 | oral cavity squamous cell carcinoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Completed | No outcome recorded |
| Phase 2/3 | NCT03086993 Comparator | Apr 2018 → Jan 2023 | intrahepatic cholangiocarcinoma | Delcath Systems Inc. | Unknown | No outcome recorded |
| Phase 2/3 | NCT03178552 Comparator | Sep 2017 → Oct 2026 expected | non-small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02709512 Background | Aug 2017 → Aug 2022 | mesothelioma | Polaris Group | Completed | No outcome recorded |
| Phase 2/3 | NCT03580395 Background | Jun 2017 → Jul 2022 | breast cancer | Hebei Medical University Fourth Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02807181 Background | Feb 2017 → Apr 2021 | intrahepatic cholangiocarcinoma | Sirtex Medical | Terminated | No outcome recorded |
| Phase 2/3 | NCT02784171 Comparator | Nov 2016 → Oct 2024 | mesothelioma | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 2/3 | NCT02591030 Comparator | Dec 2015 → Jun 2018 | bile duct cancer | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 2/3 | NCT02772107 Background | Dec 2015 → Jun 2017 | small cell lung carcinoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT01404156 Comparator | Sep 2015 → Aug 2023 | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Dr. Gordon Buduhan | Completed | No outcome recorded |
| Phase 2/3 | NCT02250872 Comparator | Dec 2014 → Feb 2018 | cancer, cisplatin toxicity | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT01631357 Background | Dec 2014 → Dec 2018 | non-small cell lung carcinoma, squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02777788 Comparator | Sep 2014 → Dec 2019 | cancer | Shanghai University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 2/3 | NCT01999933 Comparator | Nov 2013 → Nov 2016 | cervical cancer, poisoning | Mei Shi | Unknown | No outcome recorded |
| Phase 2/3 | NCT01907100 Comparator | Sep 2013 → Mar 2018 | mesothelioma | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2/3 | NCT01829178 Background | Aug 2013 → Sep 2014 | cisplatin toxicity, gastroesophageal adenocarcinoma | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT01805557 Background | Feb 2013 → Mar 2019 | diffuse large B-cell lymphoma | Fondazione Italiana Linfomi - ETS | Completed | No outcome recorded |
| Phase 2/3 | NCT01704690 Comparator | Aug 2012 → Mar 2017 | esophageal cancer | Peking University | Terminated | No outcome recorded |
| Phase 2/3 | NCT01407822 Comparator | Dec 2011 → Apr 2018 | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Unknown | No outcome recorded |
| Phase 2/3 | NCT01554397 Background | Oct 2011 → Jun 2021 | cervical cancer | University of California, San Diego | Completed | No outcome recorded |
| Phase 2/3 | NCT00939848 Background | Apr 2011 → Sep 2012 | biliary tract neoplasm | University College, London | Completed | No outcome recorded |
| Phase 2/3 | NCT01216644 Comparator | Aug 2010 → Mar 2017 | gastric cancer | Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 2/3 | NCT00997906 Background | Sep 2009 → Dec 2017 | head and neck cancer | National Cancer Centre, Singapore | Unknown | No outcome recorded |
| Phase 2/3 | NCT00930891 Background | Sep 2009 → Jul 2012 | small cell lung carcinoma | French Cooperative Thoracic Intergroup | Completed | No outcome recorded |
| Phase 2/3 | NCT01249352 Background | Jan 2009 → Nov 2013 | adenocarcinoma, esophageal cancer | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 2/3 | NCT00691236 Background | May 2008 → May 2013 | osteosarcoma | Tata Memorial Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT00651456 Comparator | Feb 2008 → Jan 2015 | mesothelioma | French Cooperative Thoracic Intergroup | Completed | No outcome recorded |
| Phase 2/3 | NCT00509561 Background | Feb 2008 → Sep 2012 | esophageal cancer | Wales Cancer Trials Unit | Unknown | No outcome recorded |
| Phase 2/3 | NCT00778908 Background | Jan 2008 → Jan 2011 | nasopharyngeal carcinoma | Guangxi Medical University | Completed | No outcome recorded |
| Phase 2/3 | NCT00450203 Background | Oct 2007 → Dec 2017 | gastroesophageal cancer | Medical Research Council | Unknown | No outcome recorded |
| Phase 2/3 | NCT00312819 Background | Mar 2006 → Dec 2009 | non-small cell lung carcinoma | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 2/3 | NCT00415818 Background | Dec 2005 → Mar 2010 | non-small cell lung carcinoma | Transgene | Completed | No outcome recorded |
| Phase 2/3 | NCT00304135 Comparator | Oct 2005 → Dec 2012 | extrahepatic bile duct carcinoma, gallbladder cancer | Federation Francophone de Cancerologie Digestive | Completed | No outcome recorded |
| Phase 2/3 | NCT00337532 Comparator | May 2005 → Jun 2007 | head and neck cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2/3 | NCT00785421 Comparator | Apr 2004 → Jan 2009 | pancreatic adenocarcinoma | CONKO-Studiengruppe | Completed | No outcome recorded |
| Phase 2/3 | NCT00385606 Background | Jan 2003 → Dec 2005 | non-small cell lung carcinoma | National Cancer Institute, Naples | Completed | No outcome recorded |
| Phase 2/3 | NCT00003643 Background | Oct 1998 → ? | extragonadal germ cell tumor, teratoma, testicular germ cell tumor | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
| Phase 3552 trials | ||||||
| Phase 3 | NCT07680790 Comparator | Sep 2026 → Dec 2031 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07613567 Comparator | Sep 2026 → Aug 2032 expected | cervical carcinoma | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07709650 Background | Aug 2026 → Jun 2031 expected | cervical cancer | Mahidol University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07706985 Comparator | Jul 2026 → Jul 2030 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT07691515 Comparator | Jul 2026 → Jan 2030 expected | intrahepatic cholangiocarcinoma | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Show all 552 trials opens the full record — a long page | ||||||
| Phase 425 trials | ||||||
| Phase 4 | NCT06931145 Background | Apr 2025 → Apr 2027 expected | small cell lung carcinoma | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06818773 Background | Feb 2025 → Dec 2026 expected | HER2 positive breast carcinoma, biliary tract cancer | Eastern Hepatobiliary Surgery Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06820255 Comparator | Jan 2025 → Jan 2026 overdue | bladder transitional cell carcinoma, renal pelvis/ureter urothelial carcinoma | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Recruiting | No outcome recorded |
| Phase 4 | NCT06457503 Background | Nov 2024 → Dec 2027 expected | nasopharyngeal carcinoma | Coherus Oncology, Inc. | Recruiting | No outcome recorded |
| Phase 4 | NCT06388135 Comparator | May 2024 → May 2026 overdue | esophageal squamous cell carcinoma | Yang Jianjun, PhD | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06276933 Background | Feb 2024 → Nov 2025 overdue | lung cancer | Tongji University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05689671 Comparator | Dec 2023 → Mar 2026 overdue | non-small cell lung carcinoma | Nikolaj Frost MD | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05730777 Background | Feb → Jul 2023 | chemotherapy-induced toxicity | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05583188 Background | Feb 2023 → Feb 2024 | non-small cell lung carcinoma | Galvanize Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT05603065 Comparator | Oct 2022 → Oct 2023 | esophageal squamous cell carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 4 | NCT06879691 Background | May 2021 → Apr 2025 overdue | head and neck cancer | Biotech Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04134247 Background | Nov 2019 → Nov 2021 | non-Hodgkin lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03986528 Comparator | Aug 2019 → Mar 2022 | non-small cell lung carcinoma | Jie Li | Unknown | No outcome recorded |
| Phase 4 | NCT03413436 Comparator | Jan → Feb 2018 | esophageal cancer | Henan Cancer Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03998696 Comparator | Jul 2017 → Jun 2018 | head and neck squamous cell carcinoma | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| Phase 4 | NCT02996214 Background | Nov 2016 → Dec 2019 | non-small cell squamous lung carcinoma | Nanjing Luye Sike Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02804646 Background | Jun 2016 → Dec 2017 | lung adenocarcinoma | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02875314 Background | Sep 2015 → Dec 2030 expected | central nervous system cancer, medulloblastoma | Parth Patel | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02195453 Background | Aug 2014 → Sep 2016 | non-small cell lung carcinoma | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
| Phase 4 | NCT02194556 Background | Jul 2014 → Jul 2017 | adenocarcinoma, non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02088515 Comparator | Dec 2013 → Oct 2016 | squamous cell carcinoma | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT01211002 Background | Oct 2010 → Dec 2011 | non-small cell lung carcinoma | Simcere Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT02497118 Background | Aug 2010 → Apr 2015 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01028729 Background | Sep 2009 → Jul 2011 | non-small cell lung carcinoma | Simcere Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT00046969 Background | Jul 2002 → Jun 2007 | anemia, cervical cancer | AGO Study Group | Completed | No outcome recorded |
| Phase not applicable69 trials | ||||||
| — | NCT07337096 Background | Jan 2026 → Dec 2027 expected | non-small cell lung carcinoma | Guangzhou University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT07202819 Comparator | Sep 2025 → May 2026 overdue | urinary bladder carcinoma | Assiut University | Recruiting | No outcome recorded |
| — | NCT06484491 Background | Sep 2025 → Oct 2027 expected | non-small cell lung carcinoma | University Medical Center Groningen | Recruiting | No outcome recorded |
| — | NCT07062484 Comparator | Jul → Dec 2025 overdue | nasopharyngeal carcinoma | Sichuan Cancer Hospital and Research Institute | Not yet recruiting | No outcome recorded |
| — | NCT06878196 Background | Mar 2025 → Dec 2028 expected | cervical cancer | Obstetrics & Gynecology Hospital of Fudan University | Not yet recruiting | No outcome recorded |
| — | NCT07495384 Background | Jan 2025 → Nov 2029 expected | ovarian cancer | The First Hospital of Jilin University | Recruiting | No outcome recorded |
| — | NCT06607926 Background | Oct 2024 → Jun 2025 overdue | non-small cell lung carcinoma | Xuanwu Hospital, Beijing | Not yet recruiting | No outcome recorded |
| — | NCT06649448 Background | Oct 2024 → Dec 2025 overdue | neutropenia | Shandong Cancer Hospital and Institute | Not yet recruiting | No outcome recorded |
| — | NCT06480864 Background | Aug 2024 → Aug 2025 overdue | small cell lung carcinoma | Yunpeng Liu | Recruiting | No outcome recorded |
| — | NCT06302465 Comparator | May 2024 → Nov 2026 expected | bone cancer | Peking University People's Hospital | Recruiting | No outcome recorded |
| — | NCT06349044 Background | Mar 2024 → Dec 2025 overdue | biliary tract cancer, colorectal adenocarcinoma, hepatocellular carcinoma | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| — | NCT06019520 Background | Aug 2023 → Feb 2024 | poisoning | Foundation University Islamabad | Unknown | No outcome recorded |
| — | NCT05667415 Comparator | Jun 2023 → Dec 2025 | — | First People's Hospital of Hangzhou | Unknown | No outcome recorded |
| — | NCT05857631 Background | May 2023 → May 2029 expected | cervical cancer, endometrial cancer | Tata Memorial Centre | Recruiting | No outcome recorded |
| — | NCT03734952 Background | May 2023 → Jan 2029 expected | — | Fujian Medical University Union Hospital | Recruiting | No outcome recorded |
| — | NCT05834413 Background | May 2023 → Jun 2027 expected | lung cancer | Shanghai University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT05821192 Background | Mar → Apr 2023 | angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified | Ou Bai, MD/PHD | Unknown | No outcome recorded |
| — | NCT05640817 Comparator | Jan 2023 → Jan 2026 | cisplatin toxicity | Tanta University | Completed | No outcome recorded |
| — | NCT05717790 Background | Dec 2022 → Nov 2024 overdue | nasopharyngeal carcinoma | Fourth Affiliated Hospital of Guangxi Medical University | Recruiting | No outcome recorded |
| — | NCT06048926 Background | Jul 2022 → Jul 2025 overdue | esophageal squamous cell carcinoma | The First Affiliated Hospital with Nanjing Medical University | Enrolling by invitation | No outcome recorded |
| — | NCT05406856 Background | May 2022 → Jul 2025 overdue | cervical carcinoma | Leiden University Medical Center | Recruiting | No outcome recorded |
| — | NCT06652022 Comparator | Jan 2022 → Dec 2026 expected | renal pelvis carcinoma, ureter cancer | Peking University First Hospital | Recruiting | No outcome recorded |
| — | NCT04823468 Background | Jul 2021 → May 2025 | nasopharyngeal carcinoma | Jinsheng Hong | Completed | No outcome recorded |
| — | NCT07605507 Background | Jul 2021 → Jul 2028 expected | cervical cancer | Siriraj Hospital | Active not recruiting | No outcome recorded |
| — | NCT04772001 Background | Mar 2021 → Oct 2025 | cervical cancer | Zhongnan Hospital | Unknown | No outcome recorded |
| — | NCT05800054 Background | Jan 2021 → Dec 2024 overdue | esophageal cancer | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| — | NCT04678791 Background | Dec 2020 → Dec 2024 | cervical squamous cell carcinoma | Peking University Third Hospital | Unknown | No outcome recorded |
| — | NCT04482829 Background | Sep → Dec 2020 | lung adenocarcinoma | Henan University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT04017377 Background | Sep 2019 → Jun 2020 | cervical cancer | Peking University Third Hospital | Unknown | No outcome recorded |
| — | NCT04284215 Background | Sep 2019 → Sep 2021 | — | Guizhou Medical University | Unknown | No outcome recorded |
| — | NCT04124198 Comparator | Mar 2019 → Dec 2025 overdue | human papilloma virus infection, oropharynx squamous cell carcinoma, virus associated tumor | Christian von Buchwald | Active not recruiting | No outcome recorded |
| — | NCT03909776 Comparator | Jan → Apr 2019 | — | Peking University People's Hospital | Completed | No outcome recorded |
| — | NCT03649048 Comparator | Nov 2018 → Sep 2028 expected | head and neck squamous cell carcinoma | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Recruiting | No outcome recorded |
| — | NCT03360760 Background | Aug 2018 → Feb 2020 | bone osteosarcoma | Peking University People's Hospital | Unknown | No outcome recorded |
| — | NCT03514849 Background | Aug 2018 → Mar 2021 | small cell lung carcinoma | Peng Zhang | Unknown | No outcome recorded |
| — | NCT03413358 Background | Jan 2018 → Oct 2019 | non-small cell lung carcinoma | BeiJing Yijiayi Medicine Techonoloy Co., Ltd. | Unknown | No outcome recorded |
| — | NCT04588168 Background | Jan 2018 → Jun 2026 | urinary bladder cancer | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT03249519 Background | Aug 2017 → Dec 2094 expected | cervical cancer | University of Erlangen-Nürnberg Medical School | Recruiting | No outcome recorded |
| — | NCT03177174 Comparator | Jun 2017 → Jan 2020 | drug-induced mental disorder | Luo yanrong | Completed | No outcome recorded |
| — | NCT05397262 Background | Mar 2017 → Dec 2098 expected | urinary bladder cancer | University of Erlangen-Nürnberg Medical School | Recruiting | No outcome recorded |
| — | NCT02951897 Comparator | Apr 2016 → Dec 2019 | lung adenocarcinoma | Third Military Medical University | Unknown | No outcome recorded |
| — | NCT02627807 Background | Dec 2015 → Dec 2020 | nasopharyngeal neoplasm | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT02701231 Background | Nov 2015 → Dec 2020 | lung cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT02289807 Comparator | Mar 2015 → Aug 2020 | nasopharyngeal carcinoma | Sun Yat-sen University | Withdrawn | No outcome recorded |
| — | NCT02194738 Background | Sep 2014 → Sep 2026 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| — | NCT02382068 Background | Aug 2014 → Jul 2017 | cancer, platinum-induced ototoxicity | Aaron Moberly | Withdrawn | No outcome recorded |
| — | NCT02208583 Comparator | Jun 2014 → Dec 2016 | hormone-resistant prostate carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT02022098 Background | Oct 2013 → Jul 2020 | head and neck squamous cell carcinoma | Debiopharm International SA | Completed | No outcome recorded |
| — | NCT03243825 Background | Nov 2012 → Jun 2015 | cervical cancer | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| — | NCT01755897 Comparator | Nov 2012 → Dec 2017 | cervical cancer | Huazhong University of Science and Technology | Completed | No outcome recorded |
| — | NCT01845779 Background | Sep 2012 → Jul 2019 | anal canal cancer, human papilloma virus infection | Centre Hospitalier Universitaire de Besancon | Completed | No outcome recorded |
| — | NCT01646853 Background | Aug 2012 → Dec 2013 | esophageal cancer | Simcere Pharmaceutical Co., Ltd | Unknown | No outcome recorded |
| — | NCT01551589 Background | Mar 2012 → Jul 2017 | esophageal squamous cell carcinoma | Chengya Chou | Completed | No outcome recorded |
| — | NCT02778308 Comparator | Jan 2012 → Jun 2018 | gallbladder cancer | Govind Ballabh Pant Institute of Postgraduate Medical Education and Research | Completed | No outcome recorded |
| — | NCT01369641 Background | Aug 2011 → Mar 2013 | cancer | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Terminated | No outcome recorded |
| — | NCT01275664 Background | Jun 2011 → May 2014 | fallopian tube cancer, ovarian Brenner tumor, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma +5 | Gynecologic Oncology Group | Terminated | No outcome recorded |
| — | NCT02549261 Background | Mar 2011 → Apr 2012 | non-small cell lung carcinoma | Biotech Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| — | NCT01285674 Background | Jan 2011 → Jan 2012 | cisplatin toxicity, platinum-induced ototoxicity | Ziv Hospital | Unknown | No outcome recorded |
| — | NCT00938145 Background | Jul 2009 → Dec 2026 expected | urinary bladder cancer | University of Cincinnati | Active not recruiting | No outcome recorded |
| — | NCT01016561 Background | Jul 2009 → Jul 2012 | cervical cancer | Abramson Cancer Center at Penn Medicine | Terminated | No outcome recorded |
| — | NCT01209520 Background | Jul 2009 → Dec 2013 | non-small cell lung carcinoma | University of Miami | Completed | No outcome recorded |
| — | NCT00825669 Comparator | Dec 2008 → Dec 2009 | hepatocellular carcinoma | Eastern Hepatobiliary Surgery Hospital | Completed | No outcome recorded |
| — | NCT01125020 Comparator | Dec 2008 → May 2010 | hepatocellular carcinoma | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| — | NCT00538525 Comparator | Sep 2007 → Apr 2008 | breast cancer | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| — | NCT00535509 Background | Jun 2007 → Jun 2013 | breast cancer | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| — | NCT00629863 Background | Sep 2004 → Sep 2009 | esophageal cancer, gastric cancer | North Wales Organisation for Randomised Trials in Health | Completed | No outcome recorded |
| — | NCT00066482 Background | Jul 2004 → Apr 2007 | childhood germ cell tumor, extragonadal germ cell tumor | Children's Oncology Group | Completed | No outcome recorded |
| — | NCT00577096 Comparator | Oct 2001 → Jun 2004 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| — | NCT00042367 Background | Apr 2000 → Dec 2005 | brain cancer | Baylor College of Medicine | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-10 | Pfizer | U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility pfizer.com ↗ |
| 2026-04-20 | Pfizer | U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility pfizer.com ↗ |
| 2026-02-27 | Pfizer | PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer pfizer.com ↗ |
| 2025-12-17 | Pfizer | PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility pfizer.com ↗ |
Evidence & citations 49 cited values
Every value below carries the sentence it was read from. 4,129 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cisplatin | “including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗4056“Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone,...” NCT00577096 ↗ “Patients presented with non-keratinizing NPC and stage AnyTN2-3M0 and plasma EBV DNA≥1500copies/ml are randomly assigned to receive TPF(paclitaxel...” NCT03306121 ↗ “One or more of the following may be assigned by the physician (physician's choice) per standard of care guidelines upon study enrollment following surgery: Cytarabine,...” NCT06861244 ↗ “The liquid chemotherapeutic drugs (Cisplatin 10.5 mg/m2 body surface in a total of 150 mL NaCl 0.9 %; Doxorubicin 2.1 mg/m2 body surface in a total of 50 mL NaCl 0.9 %) are...” NCT05303714 ↗ “Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (80mg per square meter on day 1) and tislelizumab(200mg) every three weeks...” NCT04833257 ↗ “Cisplatin: Administered by intravenous infusion during concurrent chemoradiotherapy at a dose of 30-40 mg/m² once weekly for only 5-6 treatment cycles; during sequential...” NCT06727617 ↗ “After the start of External Beam Radiation Therapy (EBRT), paclitaxel (150-175 mg/m2) or paclitaxel (albumin-bound) 222-260 mg/m2 + cisplatin (60-75 mg/m2) or carboplatin...” NCT06870565 ↗ “Fluorouracil, 1000 mg/m2 per day, intravenously for days 1 to 4; cisplatin, 70 mg/m2 (or carboplatin, area under the curve, 5) intravenously on day 1; and pembrolizumab, 200...” PMID 40965911 ↗ Nov 2025 “Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4\~6 cycles, followed by pemetrexed...” NCT04951648 ↗ “Squamous cell carcinoma: Paclitaxel (175mg/m²) or Docetaxel (60-75 mg/m²) or Nab-paclitaxel (260mg/m²) plus Carboplatin (AUC=5)/Cisplatin (75 mg/m²) (to be determined by...” NCT07608159 ↗ “BACKGROUND: The efficacy and safety of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 in combination...” PMID 24766732 ↗ Apr 2014 “Cisplatin: 75 mg/m², iv (hydration), administered on Day 1, repeated Q3W (if cisplatin-related non-hematological toxicity occurs, treatment may switch to carboplatin area under...” NCT07509099 ↗ “Acceptable histology-specific PDC regimens include carboplatin plus paclitaxel or nab-paclitaxel (any histology), carboplatin/cisplatin plus pemetrexed (nonsquamous),...” NCT06865339 ↗ “Preferably concurrent and adjuvant according to the PORTEC-3 schedule: two cycles of intravenous cisplatin 50mg/m² in the first and fourth week of the pelvic external beam...” NCT05255653 ↗ “Patients were randomly assigned to receive 3 cycles of camrelizumab (200 mg) plus chemotherapy (nab-paclitaxel, 130 mg/m2, and platinum [cisplatin, 75 mg/m2; carboplatin, area...” PMID 37535377 ↗ Oct 2023 “After induction with sintilimab plus paclitaxel, cisplatin, and nimotuzumab, participants will receive concurrent chemoradiotherapy with nimotuzumab, followed by maintenance...” NCT07310771 ↗ “Cisplatin will be administered at a calculated dose of 50mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs,...” NCT02095119 ↗ “Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations including, but not limited to: Lenvatinib,...” NCT05553782 ↗ “In this study the investigators want to demonstrate, that the single administration of intraoperative HIPEC with cisplatin and doxorubicin in addition to routine surgery delays...” NCT04180761 ↗ “Successful organoids undergo drug sensitivity testing against a predefined panel of drugs (Gemcitabine + Cisplatin,Gemcitabine + Oxaliplatin,Durvalumab + Gemcitabine +...” NCT07351591 ↗ “The patients with stage II will receive concurrent cisplatin during Intensity modulated radiotherapy (IMRT), and stage III-IVA patients will receive platinum based induction...” NCT04813705 ↗ “According to the pre-clinical results, investigators designed a prospective study, which is combined nab-paclitaxel and cisplatin with concurrent chemoradiotherapy for the...” NCT02762474 ↗ “Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days...” NCT01743157 ↗ “Nab-Paclitaxel : 260 mg/m2, intravenous infusion, d1, 3-week cycle, 3 cycles; Cisplatin: 75 mg/m2, intravenous infusion, d1, once every 3 weeks, for a total of 3 cycles;...” NCT05522985 ↗ “Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles;...” NCT04453826 ↗ “Safety & Efficacy of Neoadjuvant Immunotherapy With Durvalumab (MEDI 4736) Combined With Neoadjuvant Chemotherapy (Gemcitabine/Cisplatin or Gemcitabine/Carboplatin) in Patients...” NCT04617756 ↗ “PD-1 inhibitor (200-240mg), gemcitabine (1000mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1) every three weeks for three cycles as neoadjuvant therapy, then followed by IMRT...” NCT05340270 ↗ “PIPAC with cisplatin (7.5mg/m2 in 150 ml saline) and doxorubicin (1.5mg/m2 in 50 ml saline) in patients with peritoneal metastases (PM) from any origin besides...” NCT02320448 ↗ “Chemotherapy was either cisplatin (70 mg/m2) or carboplatin (area under the curve [AUC]4·5/AUC5, for glomerular filtration rate <50 mL/min only) administered intravenously on...” PMID 32145825 ↗ Mar 2020 “Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles; induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation;...” NCT04605562 ↗ “Patients received neoadjuvant Camrelizumab 200mg combined with chemotherapy (Cisplatin 20mg/m2, Day 1-3, Docetaxel 75mg/m2, Day 1) for 2 cycles every 21 days, followed by...” NCT04782765 ↗ “Non-small cell lung cancer (non-squamous cell carcinoma): pemetrexed plus carboplatin/cisplatin on Day 1 of each 21-day cycle for 4-6 cycles，pemetrexed every three weeks (Q3W)...” NCT06276933 ↗ “Patients receive Neoadjuvant gemcitabine (1000mg/m2 on day1 and day8 ) and cisplatin (80mg/m2 on day1)every 21days for three cycles followed by concurrent cisplatin (100mg/m2...” NCT03604965 ↗ “the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle...” NCT05772208 ↗ “The chemotherapy regimen consisted of intraperitoneal cisplatin soon after abdominal closure, postoperative intravenous cisplatin (day 14) and 5-fluorouracil (day 14-16), and...” PMID 21336855 ↗ Feb 2011 “Standard GC (gemcitabine and cisplatin) regimen: gemcitabine 1000-1200mg/m2 intravenous infusion on days 1 and 8, cisplatin 70mg/m2 on the second day of intravenous infusion,...” NCT04255771 ↗ “Peritoneal metastases (PM) from other GI or gynecologic cancers will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using cisplatin 7.5 mg/m2 in 150...” NCT03287375 ↗ “Participant will receive albumin-paclitaxel 260mg/m2 d1, isocyclophosphamide 1500mg/m2 d2-5, and cisplatin 25mg/m2 d2-5 every 21 days until disease progression, intolerable...” NCT06684327 ↗ “Neoadjuvant chemotherapy (2 cycles of cisplatin OR carboplatin accord healthcare- investigator's choice - PLUS pemetrexed fresenius AND immunotherapy (2 cycles of Opdivo PLUS 1...” NCT07121374 ↗ “Based on the PTC results, each participant will receive an individualized neoadjuvant regimen selected from gemcitabine plus cisplatin, disitamab vedotin (RC48), enfortumab...” NCT07690878 ↗ “Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations: * Liposomal Doxorubicin; * Docetaxel; *...” NCT03949283 ↗ “Gemcitabine + cisplatin (GC) regimen chemotherapy: 1250 mg/m2 was administered intravenously for 30 min on day 1 and day 8, respectively, and 100 mg/m2 was administered...” NCT06362317 ↗ “INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also...” NCT04781725 ↗ “Induction therapy: Albumin-bound paclitaxel 260 mg/m² + cisplatin 75 mg/m² (divided on days 1 - 3) + S1 calculated according to body surface area, taken twice daily (days 1 -...” NCT07085234 ↗ “cisplatin (80mg per square meter on day 1), penpulimab (200mg, day1), and anlotinib (10mg days 1-14) every three weeks for three cycles before radiotherapy, then followed by...” NCT05193617 ↗ “Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil (mDCF), followed...” NCT03288350 ↗ “The TPC regimen included NAB-paclitaxel administered at a dose of 200 mg/m2 on day 1, cisplatin at a dose of 60 mg/m2 on day 1, and capecitabine at a dose of 1000 mg/m2, taken...” NCT06664983 ↗ “Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during radiotherapy followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin...” NCT03321539 ↗ “Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2,...” NCT05182944 ↗ “Injection of Doxorubicin (2.1 mg/m2 in 50 ml NaCl 0.9%) and Cisplatin (10.5 mg/m2 body surface in 150 ml NaCl 0.9%) with a flow rate of 0.7ml/s, the therapeutic capnoperitoneum...” NCT04065139 ↗ “Pemetrexed at a dose of 500 mg/m² plus a platinum agent (carboplatin with an area under the curve (AUC) of 5 or cisplatin at a dose of 75 mg/m²) is given by intravenous...” NCT06930794 ↗ “Chemotherapy is based upon regimes with well known effectiveness in Hodgkin lymphoma. (i.e. ABVD: doxorubicin, bleomycin, vinblastine and dacarbazine and ESHAP: Etoposide,...” NCT03500133 ↗ “Induction treatment: 2 cyles of Q3W second-line plantium-based chemotherapy according to standard of care: Cisplatin or carboplatin in combination with pemetrexed, paclitaxel,...” NCT05383001 ↗ “non-Squamous NSCLC with malignant pleura effusions:Subjects receive AK112 plus Pemetrexed and Carboplatin/Cisplatin on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed...” NCT06769295 ↗ “Standard neoadjuvant chemotherapy for muscle-invasive bladder cancer, typically consisting of cisplatin-based regimens such as MVAC (methotrexate, vinblastine, doxorubicin, and...” NCT07202819 ↗ “Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was...” NCT00312728 ↗ “The treatment regimen was a combination of gemcitabine (1,000 mg/m(2)) on days 1 and 8, cisplatin (80 mg/m(2)) on day 1, and Endostar (15 mg/day) from day 1 to day 14 of a...” PMID 25198661 ↗ 2013 “Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2...” NCT01667302 ↗ “In the University Hospital Center of Besançon, 8 patients with metastatic anal cancer were treated between 2005 and 2008 by 6 cycles of chemotherapy including taxane: DCF...” NCT01845779 ↗ “It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle...” NCT02662504 ↗ “Non-squamous NSCLC subjects will receive pemetrexed/albumin paclitaxel and platinum (cisplatin/carboplatin), and squamous NSCLC subjects will receive albumin paclitaxel and...” NCT06485557 ↗ “Patients received two 21-day courses of induction CTx of TS-1 (35 mg/m2, p.o, twice daily on days 1-14), docetaxel (30 mg/m2, i.v., days 1 and 8), and cisplatin (30 mg/m2,...” PMID 31302344 ↗ Jul 2019 “Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (75 mg/m\^2) after completion of atezolizumab on Day 1 of each 21-day cycle during...” NCT04622228 ↗ “This study is to analyze the safety and efficacy of immunotherapy Triprilumab Injection combined with Gemcitabine Injection plus Cisplatin Injection in patients with advanced...” NCT04413734 ↗ “After enrollment, patients will receive first-stage treatment consisting of cisplatin plus nanoparticle albumin-bound paclitaxel chemotherapy combined with Aparolitolovureli...” NCT07283991 ↗ “Following this, a period of one to two weeks was to elapse before the initiation of Tislelizumab (200 mg), Docetaxel (75 mg/m²), and Cisplatin (75 mg/m²), on a three-week...” NCT07402538 ↗ “Patients included in the standard treatment arm will receive a combination of weekly cisplatin combined with 30 fractions of external beam radiotherapy on the primary tumour...” NCT05905315 ↗ “DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2...” NCT01014208 ↗ “Gisantinib and cisplatin chemotherapy for 6 cycles, 21 days per cycle. Gisantinib 1000mg/m2 is given intravenously on Day 1 and 8 for each cycle while cisplatin 70mg/m2 is...” NCT07261592 ↗ “Six cycles of standard induction chemotherapy consisting of cyclophosphamide, vincristine, doxorubicin (or epirubicin), etoposide, and cisplatin administered according to the...” NCT07688252 ↗ “vinorelbine and cisplatin chemotherapy (four cycles of vinorelbine [25 mg/m2 intravenously on days 1 and 8 of each 21-day cycle] plus cisplatin [75 mg/m2 intravenously on day 1...” PMID 30150014 ↗ Aug 2018 “Doxorubicin and cisplatin are administered for patients with PMA originating from gastric or ovarian cancers, whereas oxaliplatin is utilized for PMA resulting from colorectal...” NCT06743867 ↗ “According to the NCCN Guidelines (2024.V2), the first-line chemotherapy regimen for persistent, recurrent, or metastatic cervical cancer is preferably carboplatin/paclitaxel...” NCT07153952 ↗ “Dosing of chemotherapy is etoposide 90mg/m² body surface area (BSA) day 1-3 in combination with cisplatin 75mg/m² BSA on day 1 or carboplatin area under the curve (AUC) 5 mg/ml...” NCT06223711 ↗ “If the postoperatively pathological examination of the patient is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with...” NCT03514849 ↗ “Nimotuzumab Combined With Toripalimab/Gemcitabine/Cisplatin as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma: a Prospective, Single-arm,...” NCT06509009 ↗ “Cisplatin, 30 mg/m2 will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation therapy and after panitumumab for 6 weeks; treatment...” NCT00798655 ↗ “Patients received neoadjuvant chemotherapy with cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total...” PMID 29416986 ↗ Jan 2018 “Evaluate the survival of patients with metastatic or recurrent epithelial squamous or adenosquamous carcinoma of the cervix when treated with intravenous tirapazamine plus...” NCT00003369 ↗ “TPF (Paclitaxel micelles or albumin-bound paclitaxel 100 mg/m2, cisplatin 30 mg/m2, fluorouracil 200 mg/m2 IV drip + 1000 mg/m2 pump for 44 hours, leucovorin/calcium 200 mg) +...” NCT07469241 ↗ “Chemotherapy (cisplatin 40 mg/m2 intravenously or carboplatin AUC 2 intravenously) will be given on Cycle 1 Day 8, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 2 Day 8, Cycle 2 Day 15,...” NCT04620187 ↗ “Participants will undergo tumor harvest for TIL and then receive 2 to 3 cycles of pembrolizumab or pembrolizumab/platinum chemotherapy (cisplatin or carboplatin / 5-FU) as per...” NCT06236425 ↗ “Cisplatin, oxaliplatin and doxorubicin are standard, commercially available intravenous cytostatic drugs in oncologic treatment with alkylating and topoisomerase inhibitor...” NCT06421610 ↗ “pemetrexed 500mg/m2 combined with cisplatin 75mg/m2 or nedaplatin 80mg/m2 intravenously on day 1 of each 3-week cycle for four to six cycles, followed by pemetrexed maintenance...” NCT01951482 ↗ “Cisplatin 70 mg/m2 IV infusion over 4 hours Note: May divide dose over two sequential days (35 mg/m2/d x 2 days) if creatinine clearance 50-59 mL/min Day 1* (or divided over...” NCT01031420 ↗ “Concurrent chemotherapy once a week Cisplatin-based concurrent chemotherapy administered intravenously at a dose of 40 mg/m² once weekly during external beam radiotherapy for 5...” NCT07709650 ↗ “Tislelizumab 200mg, Q3W, 2-4 cycles Albumin paclitaxel 240 mg/m², adjusted according to the patient Carboplatin: AUC=5 Q3W, d1 or cisplatin: 20mg/m² iv, D1-3 Q3W or Nedaplatin:...” NCT05880082 ↗ “All patients received three cycles of 21 days each, with chemotherapy on day 1 (nab-paclitaxel 150 mg/m2 plus cisplatin 75 mg/m2) and camrelizumab 200 mg, followed by radical...” NCT05554276 ↗ “cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15, Regimen B: (cycles 2, 4, 6): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5...” NCT02066220 ↗ “Rituximab combined with Chemotherapy (Rituximab, Cyclophosphamide, doxorubicin, Vincristine, Prednisone, Ifosfamide, Gemcitabine, cisplatin, Carboplatin, Etoposide, MESNA,...” NCT07187960 ↗ “TPC induction chemotherapy regimen contains Polymeric micellar paclitaxel, which is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel, cisplatin and...” NCT06301165 ↗ “Enrolled eligible subjects will be started on systemic chemotherapy (pemetrexed and carboplatin or cisplatin) within 6 weeks of starting osimertinib, with the following outcome...” NCT06918782 ↗ “Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevacizumab.” NCT05684731 ↗ “Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.” NCT00258323 ↗ “Patients will be treated with carboplatin or cisplatin with etoposide, paclitaxel, albumin-bound paclitaxel or pemetrexed at the discretion of the treating thoracic medical oncologist.” NCT04905316 ↗ “Drugs used in chemotherapy, such as cisplatin and vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.” NCT00309972 ↗ “Induction therapy was sintilimab 200mg IV d1, bevacizumab 7.5mg/kg IV d1, albumin-bound paclitaxel 260mg/m2 IV d1 and cisplatin 80mg/m2 IV d1, once every 3 weeks, a total of 3 cycles.” NCT06752382 ↗ “radiotherapy (50.4Gy/1.8Gy/28f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W” NCT06468644 ↗ “Cisplatin 25 mg/m2 i.v. d1-3, q21d, three cycles or Carboplatin AUC 5 i.v. d1, q21d, three cycles (patients with cisplatin contraindications or renal impairment after cisplatin use).” NCT06151743 ↗ “and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 10:00-22:00)” NCT03574324 ↗ “Concurrent chemoradiation will be with platinum-based chemotherapy (cisplatin or carboplatin, with etoposide, taxane, or pemetrexed) selected at the treating physician's discretion.” NCT04364048 ↗ “Intraperitoneal chemotherapy (fluorouracil + nab-paclitaxel + cisplatin + interleukin-2) PLUS systemic chemotherapy (SOX regimen: oxaliplatin + tegafur-gimeracil-oteracil potassium)” NCT07034742 ↗ “Concurrently, Platinum-based therapy (either Cisplatin at AUC5 or Carboplatin at AUC5 or Cisplatin at 100 mg/m2) will be administered via intravenous infusion on Day 1 of each cycle” NCT06485544 ↗ “The HIPEC group was treated with cisplatin (60 mg/m2) administered with a HIPEC device on days 1 and 3 (30 mg/m2 each time), along with oral S-1, 40-60 mg, twice daily, for 14 days.” PMID 35100917 ↗ 2022 “One of either Cisplatin or Carboplatin. Both agents are potent platinum-based antineoplastic/alkylating agents administered as an IV infusion according to local practice and labels.” NCT05443126 ↗ “ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.” NCT05992597 ↗ “Most common regimen comprised of gemcitabine (1000 mg/ m2 intravenously over 30-60 min) on days 1 and 8, and cisplatin (75 mg/ m2 intravenously over 2 h) on day 1, every 21 days.” NCT06712420 ↗ “Chemotherapy: nab-paclitaxel + cisplatin/carboplatin 3 cycles; Albumin paclitaxel 260 mg/m2, cisplatin 75 mg/m2 divided into 3 days, carboplatin AUC 5 applied on the first day.” NCT06218004 ↗ “Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.” NCT05834413 ↗ “Cisplatin, 80 mg/m2 and Paclitaxel, 175 mg/m2 on DAY2, Q3W Or Cisplatin, 80 mg/m2 on DAY1 and 5-fluorouracil, 800 mg/m2 on DAYS1-5, Q3W for two cycles. All given intravenously.” NCT05213312 ↗ “Esophageal squamous cell carcinoma: cisplatin/carboplatin/nedaplatin/lobaplatin+ paclitaxel/albumin-bound paclitaxel/fluorouracil on Day 1 of each 21-day cycle for 4-6 cycles;” NCT06231680 ↗ “Patients with squamous cell carcinoma can choose paclitaxel + cisplatin/carboplatin and patients with nonsquamous cell carcinoma can choose pemetrexed + cisplatin/carboplatin.” NCT06718309 ↗ “Intervention: Drug: Carboplatin/ Cisplatin Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle” NCT03992885 ↗ “adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)” NCT05286957 ↗ “Administration of cisplatin by inhalation (pulmonary route) using single-use RS01 capsule-based device and CIS-DPI hard capsules containing 2.5 mg, 5 mg, and 10 mg cisplatin.” NCT06896890 ↗ “Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5.” NCT01278602 ↗ “Pemetrexed combined with carboplatin or cisplatin, after four cycles of combination, pemetrexed was continued as a single agent，all drugs will be administered intravenously” NCT06671379 ↗ “METHODS: This phase II, multicenter, randomized, double-blinded study assessed the safety and efficacy of adding of disulfiram to cisplatin and vinorelbine for six cycles.” PMID 25777347 ↗ Mar 2015 “PCT regimens will include both carboplatin or cisplatin plus pemetrexed (for non-squamous histology) or paclitaxel (for squamous histology) in combination with cemiplimab.” NCT07274384 ↗ “azacitidine S.C 25 mg/m2 D1,2,3,4,5 rituximab I.V. 375 mg/m2 D8 gemcitabine I.V. 1,000 mg/m2, D8,15 dexamethasone I.V. or P.O. 40 mg D8,9,10,11 cisplatin 70 mg/m2 I.V. D8” NCT03719989 ↗ “IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5” NCT01669226 ↗ “The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel/pemetrexed, cisplatin, Bevacizumab, iparomlimab and tuvonralimab, and thymosin alpha 1.” NCT07103395 ↗ “The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles.” NCT02082522 ↗ “Enrolled participants received two cycles of induction albumin-bound paclitaxel (260 mg/m2, d1), cisplatin (60 mg/m2, d1), and toripalimab (240 mg, d1) every three weeks” PMID 42028290 ↗ Apr 2026 “Induction chemotherapy consisted of three cycles of docetaxel (75 mg/m², day 1), cisplatin (75 mg/m², day 1), and penpulimab (200 mg, day 1), administered every 3 weeks.” NCT07392320 ↗ “8 weekly cycles of chemotherapy with cisplatin (30 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.” NCT01830270 ↗ “Chemotherapy was comprised of docetaxel 30 mg/m2 on days 1 and 8, cisplatin 60 mg/m2 on day 1, and S-1 70 mg/m2 on days 1 to 14, with the regimen repeated every 21 days” NCT01645748 ↗ “Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.” NCT06607926 ↗ “The neoadjuvant regimen prior to radiotherapy consists of paclitaxel 135-175 mg/m², cisplatin 75 mg/m², and Sintilimab 200 mg, administered every 3 weeks for 2 cycles.” NCT06916117 ↗ “The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel 260 mg/m², cisplatin 75 mg/m², and tislelizumab 200 mg, administered every 3 weeks.” NCT06734702 ↗ “Each treatment cycle is administered every 21-28 days and consists of chemotherapy (paclitaxel 175 mg/m², cisplatin 75-80 mg/m²) combined with camrelizumab (200 mg).” PMID 42471761 ↗ Jul 2026 “Selective Internal Radiation Therapy With Yttrium-90 Resin Microspheres Followed by Gemcitabine Plus Cisplatin for Intra-hepatic Cholangiocarcinoma: A Phase II Study” NCT02167711 ↗ “Drug: Cisplatin Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation; Concurrent cisplatin 100mg/m2, every 3 weeks for 3 cycles during radiation” NCT06712888 ↗ “Chemotherapy will combine carboplatin AUC 5mg/mL/min or cisplatin 100mg/m² every 3 weeks with 5-FU 1000mg/m²/j during 4 days every 3 weeks for a maximum of 6 cycles” NCT04747054 ↗ “Platinum-based chemotherapy options include carboplatin, cisplatin, pemetrexed, paclitaxel, or nab-paclitaxel, administered per standard of care for up to 4 cycles.” NCT04585477 ↗ “Induction chemotherapy TP regimen combined with Tislelizumab for 3 cycles: Cisplatin 37.5mg/m2 d1-2 q3w, Docetaxel 37.5mg/m2 d1and d3 q3w,Tislelizumab 200mg d3 q3w.” NCT06554028 ↗ “Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.” NCT00293085 ↗ “Concurrent with standard of care platinum doublet based chemotherapy (cisplatin + etoposide), radiation treatment plan will be delivered in three sequential phases” NCT04952480 ↗ “Gemox: Gemcitabine and Oxaliplatin； IGEV: Ifosfamide, Gemcitabine, Vinorelbine, and Prednisolone； DHAP: Dexamethasone, high-dose Cytarabine (Ara-C) and Cisplatin.” NCT04342936 ↗ “In week 1-7, standard administration of concurrent Cisplatin mono 40mg/m2 body surface area d1, 8, 15, 22, 29 (Monday of each treatment week) during radiotherapy.” NCT05504642 ↗ “Platinum based chemotherapy including cisplatin and etoposide, carboplatin and paclitaxel or cisplatin and pemetrexed (for patients with non-squamous histology).” NCT03663166 ↗ “All participants receive two cycles of albumin-bound paclitaxel (260mg/m2) on d1 and cisplatin (25mg/m2) from d1 to d3 in combination with tislelizumab (200mg).” NCT06139419 ↗ “All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .” NCT03663764 ↗ “neoadjuvant chemoimmunotherapy of Sindilizumab (200mg) plus docetaxel (75mg/m2) and cisplatin (75mg/m2) will be administered every three weeks for three cycles.” NCT06219980 ↗ “combination of chemotherapy (gemcitabine/cisplatin) + trastuzumab + pembrolizumab as first-line treatment for cholangiocarcinoma and gallbladder cancer patients” NCT06178445 ↗ “Radiochemotherapy: Cisplatin (75 mg/m² (BSA) D1#) or alternatively Carboplatin (AUC 5 D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles” NCT04602533 ↗ “The regimen will consist of gemcitabine (G) administered at a dose of 800 mg/m2, cisplatin (C) 30 mg/m2, and protein-bound paclitaxel (N) 150 mg/m2 administered” NCT04605913 ↗ “Cisplatin (CDDP), recommended by National Comprehensive Cancer Network (NCCN) as a chemotherapeutic agent in salvage treatment for recurrent high-grade gliomas” NCT02263105 ↗ “Cisplatin (30 mg/m2, QW, 2 cycles) and radiotherapy (18-26 Gy/10-13 fractions) as adjuvant chemoradiotherapy, followed by pembrolizumab (200mg, Q3W, 18 cycles)” NCT03322267 ↗ “GP chemotherapy: Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.” NCT05742750 ↗ “PD-1 inhibitor combined with chemotherapy (Paclitaxel or Albumin-bound paclitaxel plus Cisplatin or Carboplatin), administered once every 3 weeks for 2 cycles.” NCT07519486 ↗ “Intravenous concurrent or sequential adjuvant chemotherapy consists of carboplatin/paclitaxel, cisplatin/doxorubicin or cisplatin/doxorubicin/paclitaxel, etc.” NCT05524389 ↗ “three 3-weekly cycles of cisplatin 100 mg/m2 day 1 and fluorouracil 750 mg/m2/24 hours, days 1-5 with or without the addition of concurrent radiotherapy 40 Gy” PMID 30137281 ↗ Feb 2019 “Ivonescimab(20mg/kg) combined with paclitaxel polymeric micelles (≤300mg/㎡) and platinum(cisplatin 75mg/㎡or carboplatin AUC5) IV every 3 weeks for 4 cycles.” NCT07009925 ↗ “paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.” NCT06775275 ↗ “Patients will be treated with paclitaxel polymeric micelles for injection, platinum (cisplatin/carboplatin) in combination with sindilizumab for 4-6 cycles.” NCT05782426 ↗ “chemotherapy: Starting from the first week of radiotherapy and chemotherapy, cisplatin 40mg/m2 and paclitaxel 35mg/m2 were given intravenously for 30-60min” NCT05437692 ↗ “TP regimen: Docetaxel 75 mg/m2, intravenous infusion, D1， Cisplatin 75 mg/m2, intravenous infusion, D1， Every three weeks, there are two cycles in total.” NCT07055841 ↗ “Cisplatin-based concurrent chemotherapy administered intravenously at a dose of 40 mg/m² once weekly during external beam radiotherapy for 5 to 6 cycles.” NCT07605507 ↗ “Cisplatin (75mg/m2) wih routine hydration for 3 days and nab-paclitaxel (260mg/m2) will be given intravenously on day 1 in 3-week cycles for 2-3 cycles.” NCT06152978 ↗ “INRT using intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin- paclitaxel)” NCT06477692 ↗ “Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.” NCT04486833 ↗ “After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine /cisplatin regimen, until untolerable toxicity or disease progression.” NCT01843647 ↗ “The 5 chemotherapy drugs used in the Induction part of treatment are vincristine, cisplatin, cyclophosphamide, etoposide and high-dose methotrexate.” NCT02875314 ↗ “TumoCure is a polymer-based gel, loaded with Cisplatin in a dose of 100mg (10% w/w), injected to head and neck tumors locally in a single injection.” NCT05200650 ↗ “compare the efficacy and safety of camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate in study population in China” NCT04294511 ↗ “The chemotherapy treament：docetaxel( 75mg/m2/d,every21days,for4\~6cycles) and cisplatin(total dose 75mg/m2 on day 2,3,4,every21days,for4\~6cycles).” NCT00985998 ↗ “Cisplatin will be administered at 75 mg/m\^2 through a 30 minute IV infusion Q3W for 4 cycles (each cycle of 21 days) as per investigator decision.” NCT04581824 ↗ “Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines.” NCT04091867 ↗ “first-line chemotherapy must be platinum-based: cisplatin(75mg/m2 for d1) or carboplatin（AUC 5 for d1) combined with etoposide（100mg/m2 for d1-d3）” NCT02772107 ↗ “In patients with non-squamous histology, cisplatin (75 mg/m2) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.” NCT04153734 ↗ “R-HDS : Rituximab supplemented high-dose (Cyclophosphamide,Ara-C, Methotrexate, Etoposide, Cis-Platin) sequential chemotherapy with autografting.” NCT00355199 ↗ “DD-MVAC consists of Methotrexate 30 mg/m2 iv day 1, Vinblastine 3 mg/m2 iv day 2, Cisplatin 70 mg/m2 iv day 2 and Doxorubicin 30 mg/m2 iv day 2.” NCT03674424 ↗ “Cisplatin was administered every 4 weeks on the first day of each treatment cycle as a 1 to 3 hour intravenous infusion at a dose of 100mg/m\^2.” NCT00042510 ↗ “Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22 Comparator: Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29” NCT00349089 ↗ “All Patients were delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 for not less than 4 cycle, administered intravenously every 3 weeks.” NCT00940069 ↗ “Cisplatin 75mg/m2, added into 500ml 0.9% sodium chloride injection for infusion, hydration and alkalization of -1d, d1, d2, once every 3 weeks;” NCT06055153 ↗ “Patients will first receive two cycles of neoadjuvant therapy consisting of albumin-bound paclitaxel, cisplatin, toripalimab, and surufatinib.” NCT07086469 ↗ “Patients receive weekly cisplatin at 40 mg/m² intravenously on days 1, 8, 15, 22, and 29, concurrently with external beam radiotherapy (EBRT).” NCT07439497 ↗ “namely the combination of Teniposide injection and Cisplatin for the treatment of newly diagnosed central malignant germ cell tumor patients.” NCT07188441 ↗ “The purpose of this study is to find out if the study drugs nab-paclitaxel, cisplatin, and gemcitabine given together are safe and effective.” NCT03392571 ↗ “Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)” NCT02580253 ↗ “Neoadjuvant Cisplatin 75mg/m2 D1, 5FU 1000mg/m2 D2-5, for 2 cycles; Concurrent Cisplatin 30mg/m2 given with radiation 70Gy/35fraction/7weeks.” NCT01230476 ↗ “Cisplatin 75 mg/m² or Carboplatin AUC 5 IV every 3 weeks + Pemetrexed 500 mg/m² IV every 3 weeks) for 4 to 6 cycles, followed by Observation” NCT04334759 ↗ “Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle, up to 6 cycles.” NCT07062328 ↗ “Concurrent chemotherapy, 5-Fu + nedaplatin (cisplatin), every 28 days; 5-Fu 500mg/m2. D, civ d1-d5, nedaplatin (cisplatin) 80mg (70mg) /m2.” NCT03529279 ↗ “Possible regimens are either mFOLFIRINOX or NALIRIFOX or Gemcitabine Nab-Paclitaxel ± Cisplatin (GA+/-Cisplatin) or Capecitabine (Xeloda).” NCT06831136 ↗ “The third line of chemotherapy will be the EMA/CO regimen (reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.” NCT04756713 ↗ “Cisplatin was given 75 mg/m\^2 ,i.v. on day 1, pemetrexed was given 500 mg/m\^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.” NCT04181372 ↗ “Patients with pathologically proven untreated NSCLC, receiving 1st line cisplatin-vinorelbine and with an assessable lesion were eligible.” PMID 25674536 ↗ Jan 2015 “Adjuvant Chemotherapy （nab-paclitaxel 260mg/m2 d1 plus Cisplatin 75mg/m2 d1 or 25mg/m2 d1-3) in combination with Tislelizumab (200 mg Q3W)” NCT05984342 ↗ “Participants will be given intravenous administration of Camrelizumab (200mg，every 2 weeks),Cisplatin(40mg/m²，everyweek) and Radiotherapy.” NCT05311566 ↗ “docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2, 5-Fluorouracil (F) 750 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.” NCT04649476 ↗ “Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)” NCT02052960 ↗ “The chemotherapy is a fixed regimen, with Gemcitabine at a dose of 1g/m² on day 1 and day 8, and cisplatin at a dose of 80mg/m² on day 1.” NCT06969534 ↗ “Two cycles of Inductive therapy： nab-paclitaxel 250mg/ m2+cisplatin 75mg/ m2+Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles” NCT06421376 ↗ “The specific regimen is: Paclitaxel(135mg/m2,ivd, d1)+cisplatin(75mg/m2,ivd,d1-3)+Toripalimab (240mg,ivd,d1)±bevacizumab(ivd, d1)/q21d.” NCT06093438 ↗ “The recommended chemotherapy is based on the current reference combination of platinum (cisplatin or carboplatin) and etoposide (VP16).” NCT04268121 ↗ “Either cisplatin 75 milligrams/meters squared (mg/m2) administered intravenously once every 3 weeks on Day 1 of each cycle for 4 cycles” NCT04952597 ↗ “During interval surgery the patient will undergo HIPEC (Cisplatin 100mg/m2, 1h 30 infusions with sodium thiosulfate renal protection).” NCT04282356 ↗ “Participants will take eparbrutinib (QL1706) alongside cisplatin and albumin-bound paclitaxel (TC) every three weeks for three cycles.” NCT07205497 ↗ “intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.” NCT03664115 ↗ “Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3” NCT02580994 ↗ “Possible platinum doublet chemotherapy regimens are Cisplatin/Carboplatin in combination with Pemetrexed or Docetaxel or Gemcitabine.” NCT06902272 ↗ “Patients received a weekly infusion of docetaxel (25 mg/m2) and cisplatin (25 mg/m2) concurrent with hypo-RT and hypo-boost therapy.” NCT04212052 ↗ “pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve AUC 5 or pemetrexed 500 mg/m2 + cisplatin 75 mg/m2” NCT02151981 ↗ “Docetaxel 36 mg/m2 intravenous infusion over 1 hr, followed by Cisplatin 30 mg/m2 intravenous infusion over 1 hr, on day 1 and day 8” NCT03161548 ↗ “Gemcitabine 250 mg/m2 in prolonged 6 hr infusion on day 1 and 8, and cisplatin at 75 mg/m2 on day 2 of 3 week cycle, for 4-6 cycles” NCT01243632 ↗ “Etoposide 75mg/m2/iv over 90min through day 1 to day 4 and cisplatin 25mg/m2/iv over 30min through day 1 to day 3, repeat Q 3weeks.” NCT02738723 ↗ “Platinum chemotherapy may be cisplatin or carboplatin chosen based on histology and at the discretion of the treating investigator.” NCT03977467 ↗ “AP chemotherapy regimen was pemetrexed combined with cisplatin, and TP chemotherapy regimen was paclitaxel combined with cisplatin.” NCT05020457 ↗ “The GP regimen included gemcitabine administered at a dose of 1 g/m2 on day 1 and day 8, cisplatin at a dose of 80 mg/m2 on day 1.” NCT06669611 ↗ “Closed-abdomen HIPEC with cisplatin (25 mg/m2/l of perfusate) and mitomycin-C (3•3 mg/m2/l of perfusate) at 42•5°C for 60 minutes.” NCT02575859 ↗ “Cisplatin 100 mg/m2/dose Day 1 . All non-WDF patients (A2) will receive 2 cycles of mono cisplatin (100 mg/m2/dose) chemotherapy.” NCT04478292 ↗ “Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy.” NCT04672317 ↗ “Chemoradiotherapy will be administered over 30 fractions i.e. over 30 days with concomitant Cisplatin (100mg/m2) on day 1 and 21” NCT03721757 ↗ “Carboplatin (AUC 4-5) or Cisplatin (60mg/m\^2) will be administered by intravenous infusion on day 1 in a 3 week treatment cycle” NCT07376499 ↗ “Concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.” NCT03656965 ↗ “This arm will receive maximum 8 cycles of gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 delivered on day 1 and 8 every 3 weekly.” NCT02773485 ↗ “Carboplatin (AUC 4-5) or Cisplatin (60mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle” NCT06951841 ↗ “Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles” NCT02185352 ↗ “All patients will receive two cycles of induction therapy with albumin-bound paclitaxel and cisplatin combined with toripalimab.” NCT06912074 ↗ “Eligible patients will be treated with platinum-based chemotherapy (i.e. cisplatin + gemcitabine or carboplatin + gemcitabine).” NCT06820255 ↗ “Concurrent and adjuvant chemotherapy: Cisplatin, 80mg/m2, intravenous on day 1, 5fluorouracil 0.5/m2, intravenous on d1 to d4.” NCT01670409 ↗ “Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m²) Dexamethasone (120 mg) Cisplatin (100mg/m²) Cytarabine (2x2g/m²))” NCT01653067 ↗ “Additionally, gemcitabine plus cisplatin was noted to have an ORR of 74% in germline BRCA1/2 and PALB2 mutated advanced PDAC.” NCT07076212 ↗ “Patients will be treated with HIPEC using a single dose of Mitomycin 15mg/m2 and Cisplatin 50mg/m2 at 41-42 C for 90 minutes.” NCT02672865 ↗ “Carboplatinum (AUC=5) can be used instead of Cisplatin (75 mg/m2) from cycle 2 for Cisplatin induced neuro/oto/nephrotoxicity” NCT05500092 ↗ “Participants receive QL1706 every 3 weeks (Q3W) + Albumin-bound paclitaxel every 3 weeks (Q3W) + Cisplatin (Q3W) x 4 cycles.” NCT07372079 ↗ “Cisplatin: 25 mg/m2 in 500 mL of 5% glucose injection, administered intravenously over 2 hours on Day 1 and 8, repeated Q3W.” NCT07599995 ↗ “Intensity modulated radiotherapy, 70 Gy in 33 fractions M-F once daily plus cisplatin 40 mg/m2 IV weekly for up to 7 doses.” NCT06592599 ↗ “Cisplatin(75 mg/m2) + albumin-bound paclitaxel(260 mg/m2) 2)Cisplatin(25 mg/m2,d1-d3) + albumin-bound paclitaxel(260 mg/m2)” NCT04857164 ↗ “AK104 (10mg/kg, q3w) + cisplatin weekly or every 3 weeks + radiotherapy (pelvic external beam radiotherapy + brachytherapy)” NCT06998394 ↗ “Cisplatin (Platinol) will be administered intravenously, 25mg//m2 on Day 1 and Day 8 of a 21 day cycle for up to 4 cycles.” NCT04989218 ↗ “chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel” NCT00642824 ↗ “Cisplatin 50 mg/m2 administered on days 1,8, 29, 36; Etoposide 50 mg/m2 administered on days 1-5 and then again days 29-33” NCT01416961 ↗ “During RT, cisplatin will be administered either 100 mg/m2 3-weekly or 40 mg/m2 weekly, IV infusion (physician's choice).” NCT06093061 ↗ “Platinum-based chemotherapy (carboplatin: AUC5, d1 or cisplatin 75 mg/m², d1) every 3 weeks (Q3W) for a total of 4 cycles” NCT06868836 ↗ “8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5-FU at 1200 mg/m2/day for 2 days) every 2 weeks” NCT03519295 ↗ “4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks 4 cycles of cisplatin 75 mg/m2 every 3 weeks” NCT02001519 ↗ “Standard AMVAC dose is as follows: methotrexate 30mg/m2, vinblastine 3mg/m2, doxorubicin 30mg/m2, and cisplatin 70mg/m2.” NCT04506554 ↗ “Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.” NCT02873416 ↗ “Arm 1 and Arm 2 Intravenous CT: cisplatin (75mg/m² at Day 1) and gemcitabine (1250mg/m² at Days 1 and 8) every 3 weeks” NCT00415818 ↗ “All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2” NCT01829178 ↗ “furmonertinib 80mg/d for 9 weeks and cisplatin 75mg/m2 d1 iv + pemetrexed 500mg/m2 d1 iv at 21 day cycles for 3 cycles” NCT05430802 ↗ “Two cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).” NCT03963882 ↗ “Cisplatin based chemotherapy concurrently with radiotherapy, then TIL infusing following concurrent chemoradiotherapy” NCT04443296 ↗ “Chemotherapy: paclitaxel 50mg/ m2 + cisplatin 25mg/ m2, intravenous infusion of day1, once a week, a total of 5 times” NCT06885814 ↗ “Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.” NCT00423449 ↗ “Platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed are prescribed as per institutional standards.” NCT04335292 ↗ “Participants will receive either BMS-986504 + gemcitabine and carboplatin or BMS-986504 + gemcitabine and cisplatin.” NCT07532902 ↗ “Induction chemotherapy: gemcitabine and cisplatin, Q3W, 3 cycles Concurrent chemotherapy: cisplatin, Q3W, 2-3 cycles” NCT05941741 ↗ “Cisplatin 75mg/m² or carboplatin AUC 5mg/mL/min, pemetrexed 500mg/m² and pembrolizumab 200mg for non squamous NSCLC.” NCT04547504 ↗ “Etoposide 50mg/m2, ivgtt, d1-d5; cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles” NCT02215356 ↗ “paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.” NCT03904927 ↗ “AP-treated patients received cisplatin (60 mg/m(2), day 1) and amrubicin (40 mg/m(2), days 1-3) once every 21 days.” PMID 27061082 ↗ Apr 2016 “Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8.” NCT00275951 ↗ “PD-1 inhibitor plus AP regimen chemotherapy (Pemetrexed + Carboplatin or Cisplatin, every 3 weeks) for 4-6 cycles.” NCT07337096 ↗ “Standard dosage of drugs for each PIPAC: Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m²) or Oxaliplatin (92 mg/m²)” NCT02604784 ↗ “Lipusu (T) + Cisplatin (DDP) program: T 135mg/m2 ivgtt, d1, 3week\*2cycles; DDP 75mg/m2 ivgtt, d2, 3week\*2cycles;” NCT05775419 ↗ “Cisplatin (40mg/m2), D1 intravenous drip, start the first week of radiotherapy, use it continuously for 4-6 weeks.” NCT04766359 ↗ “Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.” NCT02873520 ↗ “Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.” NCT02862561 ↗ “Aumolertinib 110 mg QD in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5)” NCT04923906 ↗ “Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles” NCT01927744 ↗ “HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes” NCT03842982 ↗ “TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin.” NCT00576056 ↗ “Neoadjuvant Chemotherapy with * Toripalimab + Cisplatin + Docetaxel OR * Toripalimab + Carboplatin + Docetaxel” NCT07209189 ↗ “Cisplatin: 80mg/m2, ivgtt, d1 (high-dose cisplatin antiemetic and hydration regimen), q3w，repeat 4 \~ 6 cycles.” NCT06177301 ↗ “3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.” NCT02340936 ↗ “Etoposide 100mg/m\^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m\^2 ivggt on days 1, 2, 3, repeated every 21 days.” NCT03963193 ↗ “Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.” NCT02115464 ↗ “Immuno-chemotherapy regimen included etoposide, cisplatin, iparomlimab and tuvonralimab, and thymosin alpha 1.” NCT07103408 ↗ “Cisplatin: 75mg/m², intravenous infusion, on Day 1, every 3 weeks (Q3W), for 3 cycles of neoadjuvant treatment” NCT06952621 ↗ “cisplatin + paclitaxel/ albumin-bound paclitaxel/ gemcitabine/ Pemetroxel+ Toripalimab (cisplatin 75mg/m2 (D1)” NCT04606303 ↗ “The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU.” NCT03691441 ↗ “Pemetrexed (500 mg/m2) plus carboplatin (AUC5) or cisplatin（75 mg/m²）on Day 1 of 21day cycles (every 3 weeks)” NCT07063329 ↗ “Patients receive cisplatin intravenously (IV) over 1 hour and paclitaxel IV over 1 hour on days 1, 8, and 15.” NCT00680758 ↗ “In CG, occlusive IPCI with cisplatin (30-60 mg) and fluorouracil (500-600 mg/m2) was applied twice, biweekly.” PMID 28529748 ↗ Apr 2017 “Patients will receive two cycles of gemcitabine, cisplatin, nimotuzumab, and sintilimab as induction therapy.” NCT06490341 ↗ “Docetaxel plus cisplatin chemotherapy regimen was delivered as chemotherapy and concurrent chemoradiotherapy.” NCT01889303 ↗ “platinum compound (cisplatin 75 mg/m2 or carboplatin area under the curve of 5 mg per milliliter per minute)” NCT05623319 ↗ “Gemcitabine: 1000 mg/m² on Day 1 and Day 8; Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles” NCT06605131 ↗ “Etoposide combined with cisplatin or carboplatin, administered every three weeks for a total of four cycles.” NCT06719700 ↗ “Cisplatin based concurrent chemotherapy, including cisplatin as a single agent or cisplatin plus Paclitaxel.” NCT03955367 ↗ “Patients will receive three cycles of atezolizumab in combination with carboplatin/cisplatin plus etoposide.” NCT06768307 ↗ “The dosage of cisplatin is 40 mg/m2, administered once weekly during radiotherapy for a duration of 5 weeks.” NCT06353061 ↗ “cisplatin administered by intravenous infusion on day 1 of each cycle at 80 mg/m2 every 3 weeks for 3 cycles” NCT06059261 ↗ “Patients will most often receive cisplatin based therapy for a period of three months (four 21 day cycles).” NCT00938145 ↗ “Platinum-based agent: Cisplatin 75 mg/m² or Carboplatin AUC 5, intravenous infusion on Day 1, every 3 weeks” NCT07381543 ↗ “Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5” NCT00580372 ↗ “followed by intravenous cisplatin (75 mg per square meter), administered during a period of 0.5 to 3 hours” NCT01425736 ↗ “Cisplatin: total 75 mg/m2, once a day, continuous intravenous drip for more than 3 hours, days 1 to 3, q3w” NCT05668767 ↗ “Concurrent Chemotherapy consists of weekly albumin-bound paclitaxel 50mg/m2, d1 plus cisplatin 25mg/m2，d1.” NCT06545747 ↗ “Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.” NCT03588494 ↗ “Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks” NCT03308552 ↗ “Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks” NCT03328234 ↗ “Concurrent chemotherapy with cisplatin at 75mg/m2 during radiotherapy will be the most preferred regimen.” NCT05772377 ↗ “with intraperitoneal paclitaxel and cisplatin, and oral S-1 in gastric cancer with peritoneal metastasis.” NCT02995850 ↗ “ESHAP (etoposide, methylprednisolone, cisplatin, cytosine arabinoside) chemotherapy was invented in 1994.” NCT00930605 ↗ “chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion” NCT03067610 ↗ “Patients receive ivonescimab in combination with nab-paclitaxel + cisplatin for 3 cycles before surgery.” NCT06444009 ↗ “30 Gy or 70 Gy of radiation in combination with standard chemotherapy (cisplatin, carboplatin, and 5-FU)” NCT06563479 ↗ “Pemetrexed and cisplatin are the standard chemotherapy regimen to treat malignant pleural mesothelioma.” NCT01675765 ↗ “Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation.” NCT05622474 ↗ “Chemotherapy options include: carboplatin or cisplatin along with pemetrexed, paclitaxel or gemcitabine” NCT06800339 ↗ “Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.” NCT04995120 ↗ “Chemotherapy: DDMVAC (6 cycles) or Gemcitabine-Cisplatin (4 cycles) Immunotherapy: Avelumab (6 cycles)” NCT06686381 ↗ “pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.” NCT03322566 ↗ “Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles” NCT00379262 ↗ “Cisplatin： Cisplatin intravenous infusion was administered at a dose of 30 milligrams per square meter” NCT04453930 ↗ “SHR-1316(Adebrelimab)，20mg/kg,+Cisplatin 75mg/m2, d1+ etoposide 100mg/m2, d1,d2,d3, q3w, iv, 4 cycles.” NCT05496166 ↗ “docetaxel 40 mg/m2 on day 1, cisplatin 40 mg/m2 on day 1, and fluorouracil 1200 mg/m2 on days 1 and 2” PMID 41202834 ↗ Nov 2025 “These drugs include Cisplatin or Oxaliplatin and 5-fluorouracil (5 FU) in combination with Docetaxel.” NCT04931420 ↗ “Intraperitoneal docetaxel, intravenous cisplatin and oral TS-ONE every 3 weeks for 3 cycles then stop” NCT02024841 ↗ “Combination drugs : docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days” NCT03114280 ↗ “Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.” NCT02518802 ↗ “Initial Cytoreduction is performed with DHAP- protocol using dexamethasone, cytarabine and cisplatin” NCT00384553 ↗ “Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles.” NCT04351555 ↗ “Cisplatin or carboplatin will be carefully chosen according to each patient's Creatinine Clearance.” NCT05461261 ↗ “Chemotherapy list: * Liposomal Doxorubicin; * Docetaxel; * Paclitaxel; * Carboplatin; * Cisplatin;” NCT03632798 ↗ “cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy” NCT04453813 ↗ “Or cisplatin: 75-80mg/m2 intravenously, given at weeks 1, 4, 7, 10, 13, 16 for a total of 6 weeks.” NCT06371482 ↗ “Chemotherapy options include carboplatin/ paclitaxel and cisplatin/etoposide per standard of care.” NCT03745222 ↗ “Gemcitabine 1.0g/m2, D1 and D8; Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles” NCT03907826 ↗ “possible regimens are either mFOLFIRINOX or Gemcitabine Nab-Paclitaxel +/- Cisplatin (GemAbraxane)” NCT04990609 ↗ “Cisplatin-base chemotherapy as per the designated schedule, alongside standard hydration protocol.” NCT06019520 ↗ “Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion” NCT01440270 ↗ “concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy)” NCT04223024 ↗ “participants receive an intravenous (IV) infusion of paclitaxel 135 mg/m2plus cisplatin 50 mg/m2.” NCT05310331 ↗ “* Carboplatin area under curve 6 mg/mL per minute per IV route or Cisplatin 75 mg/m² per IV route” NCT04042558 ↗ “Nab-Paclitaxel, Cisplatin, and Capecitabine Chemotherapy Combined With Apatinib and Camrelizumab” NCT06438627 ↗ “Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks” NCT02648425 ↗ “Days 22-57-92: Cisplatin: 80 mg/m² over 4 hours + Vincristine:1.5 mg/m² (maximal dose 2 mg) i.v.” NCT02265770 ↗ “The HIPEC regimens are Docetaxel 75 mg/m\^2 and cisplatin 75 mg/m\^2, respectively, 43°C, 90min.” NCT03373058 ↗ “Carboplatin (AUC = 4-5, Day 1) / Cisplatin (75 mg/m2, Day 1) (as determined by the investigator)” NCT06764368 ↗ “with investigators' choice of either cisplatin (75-80mg/m2, Q3W) or carboplatin (AUC=5\~6, Q3W).” NCT04675697 ↗ “Squamous carcinoma: docetaxel 60 mg/m2, d1 + cisplatin 25 mg/m2, d1-3 or carboplatin AUC=4-6 d1” NCT05472467 ↗ “Cisplatin 75 mg/m2 will be administered as an intravenous infusion over 2 hours, every 3 weeks” NCT05394233 ↗ “For Arms M2 and E2: Cisplatin plus 5-FU or oxaliplatin plus capecitabine will be administered.” NCT06731478 ↗ “First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.” NCT01719536 ↗ “cisplatin 75mg/㎡ was added to 3000ml of physiological saline for intraperitoneal hot infusion.” NCT06544460 ↗ “Cisplatin or Carboplatin: Cisplatin 75 mg/m² IV on Day 1 or Cisplatin 25 mg/m² IV on Days 1-3” NCT07091305 ↗ “Docetaxel and Cisplatin x 3 cycles followed by Transoral robotic surgery and neck dissection.” NCT04277858 ↗ “Albumin paclitaxel 125mg/㎡ d1, 8 Cisplatin 75mg/㎡ d1-3 1/21d✖6 or carboplatin AUC6 d1 1/21d✖6” NCT04499118 ↗ “Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 infused on both day 1 and day 8 of a 21-day cycle.” NCT05422690 ↗ “Albumin paclitaxel 125 mg / m2, D1, D8 + cisplatin 75 mg / m2, D1, every 3 weeks for 1 cycle” NCT05381636 ↗ “Cisplatin 75 mg/m² on Days 1, 2 and 3 (D1/D2/D3), intravenous infusion, every 3 weeks (Q3W).” NCT07437898 ↗ “Carboplatin (AUC = 5 mg/mL/min, Q3W, IV) or Cisplatin (75 mg/m², Q3W, IV) for up to 4 cycles” NCT07174908 ↗ “neoadjuvant chemotherapy is based on the combination of etoposide and cisplatin/carboplatin.” NCT03523234 ↗ “B. P: Cisplatin 30 mg/m2, 2 h IVF, weekly following paclitaxel, week 1 to week 5 during CRT.” NCT03623737 ↗ “Cisplatin 75mg/m² IV drip for one day or two-three days total injection,21 days for a cycle.” NCT02195453 ↗ “Nab-paclitaxel(Albumin-bound paclitaxel) 110-130mg/ m2，d1，d8; Cisplatin 60-75mg/ m2，d1；Q3W；” NCT06086457 ↗ “cisplatin 75mg/m2 or carboplatin AUC 5, intravenous infusion on the first day of each cycle” NCT04124731 ↗ “Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.” NCT01069081 ↗ “All trans tretinoic acid+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)” NCT06703047 ↗ “followed by intravenous cisplatin (75 mg/m2), administered during a period of 2 to 3 hours” NCT01542931 ↗ “Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles” NCT00775385 ↗ “Drug: Cisplatin Cisplatin is given at 75mg/m2 intravenously on day 1 of each 21 day cycle.” NCT03833466 ↗ “followed by intravenous cisplatin(75 mg/m2), administered during a period of 2 to 3 hours” NCT02285543 ↗ “followed by intravenous cisplatin(75 mg/m2), administered during a period of 2 to 3 hours” NCT02285530 ↗ “(carboplatin or cisplatin based on investigator's choice) + pemetrexed intravenously (IV)” NCT05607550 ↗ “sequential concurrent chemoradiotherapy (50 Gy/25 fractions with two cycles of cisplatin)” NCT07447570 ↗ “Combination of cisplatin and docetaxel administered as two cycles given every three weeks” NCT00460551 ↗ “Serplulimab+Paclitaxel+Cisplatin/Carboplatin Serplulimab+Pemetrexed+Cisplatin/Carboplatin” NCT05775796 ↗ “then receive Sintilimab + Carboplatin/Cisplatin + Pemetrexed every 3 weeks for 3 cycles.” NCT07038460 ↗ “Cisplatin 75 mg/mq will be administered as a 2 hours intravenous infusion every 3 weeks.” NCT02439489 ↗ “plus cisplatin 50 mg/m2 intravenously on days 1, 8, 29, and 36 for two cycles of 4 weeks” PMID 39615497 ↗ Nov 2024 “Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks” NCT01003964 ↗ “Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous Carboplatin” NCT02709512 ↗ “Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W” NCT05574998 ↗ “plus cisplatin 75 mg/m2 on day 1 of each cycle for adenocarcinoma or squamous carcinoma” PMID 34280355 ↗ Jul 2021 “All subjects will receive treatment with JSKN033 + cisplatin/carboplatin ± bevacizumab.” NCT07497074 ↗ “Cisplatin 75mg/m\^2, IV infusion, on day-1 at every cycle of 21days, 4 cycles at most.” NCT06380348 ↗ “PIPAC procedure will be carried out with either oxaliplatin or doxorubicin/ cisplatin.” NCT04956068 ↗ “Neoadjuvant Chemotherapy with paclitaxel (or albumin - bound paclitaxel) and cisplatin” NCT06957938 ↗ “PF : fluorouracil 750-1000mg/m2, CIV 96 hours，cisplatin 75mg/m2, d1, iv, q4w，2 cycles.” NCT07112833 ↗ “Toripalimab 240mg, d1; docetaxel 75mg/m2 d1; cisplatin 75mg/m2 d1, q21d, for 2 cycles” NCT04296747 ↗ “Cisplatin (cis-dichlorodiammineplatinums II) is a first generation platinum compound.” NCT04789941 ↗ “Intravenous, pemetrexed 500 mg/m\^2 plus either cisplatin (75 mg/m\^2) or carboplatin” NCT05338970 ↗ “Cisplatin 80 mg/mq iv day 1 and Gemcitabine 1250 mg/mq iv days 1 and 8 every 21 days;” NCT03823625 ↗ “Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)” NCT01102231 ↗ “Albumin-bound paclitaxel 50 mg/m² plus cisplatin 25 mg/m², administered weekly (QW).” NCT07086456 ↗ “Chemotherapy Regimen 1：Pemetrexe 500 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1” NCT01665417 ↗ “Drug: Cisplatin: Cisplatin will be administered at 60 mg/m2 by intravenous infusion” NCT01406249 ↗ “Cisplatin: 100mg/m2, injected intravenously every 3 weeks, 8 cycles (period 21 days)” NCT05241132 ↗ “Doxorubicin 60 mg/m², Day 1 Ifosfamide 3 g/m² Day 1 and 2 Cisplatin 100 mg/m², Day 2” NCT03643133 ↗ “cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin” NCT01091168 ↗ “Serplulimab (300mg) + Albumin-bound paclitaxel + Cisplatin/Carboplatin, Q3W, 3cycles” NCT07403435 ↗ “Cisplatin 100 mg/m2 or Carboplatin Area under the curve (AUC) = 5) on days 1, 22, 43” NCT02819752 ↗ “Cisplatin , a kind of chemotherapeutics, can enforce the anti-tumor effects of TMZ.” NCT01670890 ↗ “cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy” NCT06455410 ↗ “Thymoma: Cisplatin+Amycin+Cyclophosphamide Thymic carcinoma: Carboplatin+Paclitaxel” NCT04667793 ↗ “Camrelizumab combined with cisplatin for advanced cutaneous squamous cell carcinoma” NCT05490485 ↗ “The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.” NCT00825669 ↗ “Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles” NCT04520035 ↗ “3 cycles of albumin-bound paclitaxel（260 mg/m2 D1 q3w）+ cisplatin（75 mg/m2 D1 q3w）” NCT07339488 ↗ “Aim is to apply minimum 5 cycles of cis-Platin, in particular in advanced disease.” NCT03617133 ↗ “Cisplatin+paclitaxel will be administered once every three weeks for four cycles.” NCT03927495 ↗ “NACT with Taxane combined with cisplatin and Fertility-sparing Treatment Strategy” NCT02624531 ↗ “cisplatin 80 mg/m\^2 IV Q3W, and 5-FU 600 mg/m\^2/day IV infusion on Days 1 to 5.” NCT04813523 ↗ “Standard of Care Chemotherapy cisplatin by intravenous administration at 80 mg/m2” NCT05315830 ↗ “First-line: Pemetrexed (500 mg/m²) + cisplatin (75 mg/m²) or carboplatin (AUC 5).” NCT07131345 ↗ “Starting from the first week of radiochemotherapy, cisplatin 40 mg/m2 was given.” NCT06128460 ↗ “2. PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)” NCT01336543 ↗ “Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP)” NCT04251065 ↗ “2 to 4 cycles of IV P-DHAP (pembrolizumab, dexamethasone, cytarabine, cisplatin)” NCT04838652 ↗ “PAXG (cisplatin, nab-paclitaxel, capecitabine, and gemcitabine) over mFOLFIRINOX” PMID 41275879 ↗ Nov 2025 “Procedure: TACE cisplatin 75 mg/sqm, day1, every 6 weeks; fotemustine 100 mg/sqm” NCT05647954 ↗ “Cisplatin injection: 30 mg (6 mL) per vial; 75 mg/m² intravenously every 3 weeks” NCT07492342 ↗ “vincristine, cyclophosphamide, cisplatin, etoposide with or without methotrexate” NCT06193759 ↗ “cisplatin 75mg/m 2 d1, or paclitaxel 175mg/m 2 d1, cis Platinum 25mg/m 2 d1-3 IV” NCT05183958 ↗ “Cisplatin-based induction chemotherapy will be administered every three weekly.” NCT06846450 ↗ “Paclitaxel+ Cisplatin, Q3W × 4cycles or Paclitaxel+ Carboplatin, Q3W × 4 cycles” NCT05978193 ↗ “On Cycle 1 Day 15, patients receive docetaxel (75 mg/m2), cisplatin (75 mg/m2).” NCT00130780 ↗ “salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP)” NCT00003143 ↗ “docetaxel 60 mg/m2 delivered on day 1 and cisplatin 80 mg/m2 delivered on day 1” NCT02969473 ↗ “Cisplatin 75 mg/m2, IV IV doses on D1 of each chemotherapy cycle, for 4 cycles” NCT01249352 ↗ “Platinum: Cisplatin 75 mg/m² by IV infusion or Carboplatin AUC=5 mg/mL/min Q3W” NCT06978829 ↗ “Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin.” NCT03393507 ↗ “For cycle 1/4/5/6. Etoposide 100mg/m2, d1-3, q3w; Cisplatin 25mg/m2 d1-3, q3w.” NCT04882033 ↗ “GC chemotherapy D1 Cisplatin 25mg/m2+ gemcitabine 1g/m2, D8 gemcitabine 1g/m2” NCT04527679 ↗ “Cisplatin: 25 mg/m² as iv-infusion on days 2, 3\* and 16, 17\* of each course” NCT01077427 ↗ “Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w.” NCT05872724 ↗ “Cisplatin 60mg/m2 or Cisplatin 45mg/m2 Carboplatin AUC 5 or Carboplatin AUC 4” NCT03567642 ↗ “Four drugs will be adriamycin, high-dose methotrexate, cisplatin, ifosfamide.” NCT03390946 ↗ “cisplatin 75mg intravenously on days 2 and 3 every 3 weeks (iv.15-30 minutes)” NCT02844114 ↗ “Drug: Cisplatin, 75mg/m2 D1 IV Q3W or Carboplatin AUC 5-6mg/ml/min D1 IV Q3W” NCT06714708 ↗ “Cisplatin 50 mg 2, ivgt, D1, 8, 29, 36, etoposide 50 mg 2, ivgt, D1-5, 29-33” NCT04182698 ↗ “Cisplatin :Participants will receive 75 mg/m\^2, day 1 , 21 days/cycle, Q21D” NCT05186506 ↗ “Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day” NCT03708042 ↗ “docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2 through intravenous infusion” NCT05798793 ↗ “Nano-paclitaxel 260 mg/m2, d1, ivgtt, q3w+Cisplatin 75mg/m2, d1, ivgtt,q3w.” NCT05892237 ↗ “Cisplatin 60mg/m\<2\> day 1 of each 21-day cycle until disease progression.” NCT00388960 ↗ “Irinotecan 65mg/m2 + Cisplatin 30mg/m2 IV on D1,D8 every 3 weeks X 3 cycles” NCT00620269 ↗ “The choice between Carboplatin or Cisplatin is entrusted to the clinician.” NCT06378892 ↗ “Cisplatin, vincristin, etoposide, cyclophosphamide, high-dose methotrexate” NCT07291102 ↗ “Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1” NCT00705627 ↗ “Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.” NCT02876861 ↗ “Tislelizumab 200mg D1, Nab Paclitaxel 260mg/m² D1, Cisplatin 75mg/m² D1-3” NCT07145931 ↗ “Platinum includes caboplatin or cisplatin, which is chosed by phycisians.” NCT05407155 ↗ “with mitomycin c and cisplatin will be administered following gastrectomy” NCT01683864 ↗ “cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle)” NCT03986528 ↗ “Ivonescimab 20mg/kg + chemotherapy (Cisplatin + Paclitaxel) Q3W, 3 cycles” NCT06814158 ↗ “Hyperthermic intraperitoneal chemotherapy (HIPEC) with 100mg/m2 cisplatin” NCT03150628 ↗ “Paclitaxel-binding albumin 260 mg/m2，d1，ivgtt；cisplatin 75 mg/m2，d1，ivgtt” NCT04060459 ↗ “Cisplatin: 70mg/m2 or Carboplatin: AUC=4.5/5, intravenous (IV) infusion.” NCT06592326 ↗ “Cisplatin 3.5 mg/kg + mannitol 0.4 g/kg in D5 NS (1000 ml/m2) over 6 hrs” NCT00042367 ↗ “weekly infusion of docetaxel (25mg/m2) and cisplatin (25mg/m2) during RT” NCT04951063 ↗ “Cisplatin and gemcitabine were locally sourced with commercial products.” NCT01342965 ↗ “Gemcitabine plus Cisplatin plus Toripalimab(GP plus Toripalimab regimen)” NCT07362979 ↗ “NC-6004 is a polymeric micelle-containing cisplatin as an active moiety.” NCT03109158 ↗ “New adjuvant chemotherapy 3 cycles with Paclitaxel and Cisplatin 70mg/m2” NCT02595554 ↗ “gemcitabine 1000 mg/m2, D1,D8; cisplatin 80 mg/m2,D1；Q3W, up to 6 cycles” NCT05513573 ↗ “single-agent cisplatin or carboplatin, or platinum-doublet chemotherapy” PMID 39914419 ↗ Feb 2025 “Standard radiation and chemotherapy (cisplatin and pemetrexed) + RAD001” NCT01063478 ↗ “Etoposide 100mg/m\^2 d1-3+ cisplatin 75mg/m\^2 d1-3 or Carboplatin AUC5” NCT07172412 ↗ “cisplatin 60 mg/m2 on the first day, arterial infusion for half an hour” NCT06859684 ↗ “Cisplatin: 50 mg/m2 body surface area, on the first day, every 3 weeks.” NCT04188847 ↗ “and cisplatin (75 mg/m², intravenous infusion) or carboplatin (AUC = 5)” NCT07244965 ↗ “Doublet 1: cisplatin + 5-fluorouracil Doublet 2: cisplatin + paclitaxel” NCT06010303 ↗ “Paclitaxel (90 mg/m2)on day 1 and 8 Cisplatin (40 mg/m2)on day 1 and 8.” NCT00452803 ↗ “Cisplatin: 75 mg/m ² or carboplatin：AUC=5 mg/mL/min on Day 1 of 21-day.” NCT07272590 ↗ “Standard of care therapy, weekly, with either Cisplatin or Carboplatin” NCT06234748 ↗ “Gemcitabine combined with cisplatin regimen combined with Tislelizumab” NCT06383780 ↗ “pemetrexed or gemcitabine in combination with cisplatin or carboplatin” NCT01951586 ↗ “Cisplatin 75 mg/m² IV on Day 1 of each of the first four 21-day cycles” NCT00403403 ↗ “Radiotherapy followed by Adebrelimab+Bevacizumab+Cisplatin/Carboplatin” NCT07638852 ↗ “cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle” NCT01453205 ↗ “Cisplatin, pemetrexed, gemcitabine, carboplatin, paclitaxel, docetaxel” NCT06623656 ↗ “Cisplatin 75-80 mg/m², administered intravenously at a 1 mg/min rate.” NCT06866951 ↗ “squamous: gemcitabine + cisplatin/carboplatin or taxane + carboplatin” NCT04702009 ↗ “3 cycles, each 21 days, of Cisplatin 80mg/m2 plus Paclitaxel 175mg/m2” NCT03815903 ↗ “Cisplatin will be given at a dose of 75 mg/m² on day 1 of each cycle.” NCT06784206 ↗ “Cisplatin(30 mg/m2) diluted into 150 ml of 0.9% NS for IV over 30 min” NCT01441349 ↗ “Cisplatin is given 80 mg/m\^2 through a vein on day 1 every 21 days.” NCT00555672 ↗ “paclitaxel (albumin binding) combined with gemcitabine and cisplatin” NCT04723030 ↗ “etoposide 100 mg/m2 and cisplatin 20 mg/m2, day 1-2, repeated weekly” NCT05139095 ↗ “Concurrent cisplatin (100 mg/m², d1-3, Q3w, maximum to three cycles)” NCT05145660 ↗ “Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously” NCT06037655 ↗ “Drug: Cisplatin 75 mg/m2 on Day 1 of each 3-week cycle, for 2 cycles” NCT06354530 ↗ “Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2.” NCT02883543 ↗ “Cisplatin or anthraxyline and cyclophosphamide (AC) administered IV” NCT07169851 ↗ “Cisplatin 25 mg/m2 IV over 60 minutes on day 1 and day 8 q 3 weekly” NCT07062263 ↗ “Tislelizumab in Combination With Chemotherapy(etoposide/cisplatin )” NCT06851819 ↗ “chemoradiation in the form of cisplatin plus conformal radiotherapy” NCT03274284 ↗ “weekly albumin-bound paclitaxel (50 mg/m²) and cisplatin (25 mg/m²)” NCT06730308 ↗ “Intravenous (through a vein) infusions of pemetrexed and cisplatin.” NCT01445392 ↗ “Drug: Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1” NCT04158440 ↗ “Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W” NCT05023109 ↗ “Drug: GP chemotherapy gemcitabine 1000mg/m2 + cisplatin 25mg/m2 Q3W” NCT05019677 ↗ “chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin 75mg/m2 IV D1” NCT03890185 ↗ “Gemcitabine 1000 mg/m2 d 1, 8 + cisplatin 75 mg/m2 1 every 3 weeks;” NCT04055038 ↗ “cisplatin 75 mg/m² or carboplatin AUC 5, plus pemetrexed 500 mg/m²” NCT07084610 ↗ “Concurrent chemoradiotherapy (CRT) with weekly doses of cisplatin.” NCT07168785 ↗ “Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2” NCT00070629 ↗ “Platinum drug must be one of cisplatin, carboplatin or nedaplatin;” NCT06424899 ↗ “Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles” NCT04280822 ↗ “Cisplatin 100 mg/sqm iv day 1 of every cycles in 24-hours infusion” NCT02374424 ↗ “Gemcitabine (G) + Cisplatin (P) + Dexamethasone (DXM)] ± Rituximab” NCT06520163 ↗ “cisplatin - 100 mg/m\^2/24 hrs continuous on day 1 of dosing cycle” NCT00823719 ↗ “and cisplatin 80 mg/m\^2, IV, on Day 1 of Cycles 1 through 4 or 6” NCT00531960 ↗ “Cisplatin 50 mg/m² IV on day 1 or carboplatin AUC 4-5 IV on day 1” NCT07092696 ↗ “SCLC patients will receive six cycles of cisplatin and etoposide.” NCT02701231 ↗ “INJ. CISPLATIN 75 MG/M 2 IN 500 ML NS IV OVER 1 HOUR ON DAY1 ONLY” NCT06737822 ↗ “concurrent chemotherapy consists of cisplatin (75 mg/m2, day 1-3)” NCT03622827 ↗ “consisting of cisplatin 60-75 mg/m² on days 1 and 2 of each cycle” NCT07340489 ↗ “PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3” NCT00930891 ↗ “Cisplatin 80-100mg/m2 was used every 3 weeks during radiotherapy.” NCT03101514 ↗ “Gemcitabine 1000 mg/m² and cisplatin 25 mg/m² IV on Days 1 and 8” NCT07053150 ↗ “Drugs used in PC chemotherapy includes Pemetrexed and Cisplatin.” NCT04482829 ↗ “teripalimab 240mg d1 paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1” NCT03985670 ↗ “Chemotherapy: Paclitaxel 135mg/m2 d1+cisplatin 25mg/m2 d1-3 q28d” NCT06964568 ↗ “* Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.” NCT04900623 ↗ “ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin)” NCT00568815 ↗ “carboplatin 200-250mg/m2, IV, Q2w or cisplatin 50mg/m2, IV, Q2w” NCT05898373 ↗ “followed by cisplatin 75 mg/m2 as IV over approximately 2 hours” NCT05765084 ↗ “pemetrexed/paclitaxel/nab-paclitaxel plus carboplatin/cisplatin” NCT07603661 ↗ “Three weekly concurrent chemotherapy with cisplatin 100 mg /m2” NCT03923998 ↗ “Carboplatin, paclitaxel, nab-paclitaxel, cisplatin, pemetrexed” NCT03774732 ↗ “Radiation Therapy in combination with Chemotherapy (Cisplatin)” NCT03623646 ↗ “PIPAC with doxorubicin and cisplatin at escalating dose levels” NCT04811703 ↗ “neoadjuvant ivonescimab combined with paclitaxel and cisplatin” NCT07130240 ↗ “* Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)” NCT00577512 ↗ “cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3)” NCT02404571 ↗ “an intravenous administration of 100 mg/m2 cisplatin on day 1” NCT04398056 ↗ “Cisplatin (75 mg/m2) was administered intravenously on day 1” NCT02223611 ↗ “Drug: Cisplatin Injection Specification: 75mg/m2, IV D1 Q3W.” NCT05174325 ↗ “Cisplatin: administered on Day 1, 75-80mg/m² via IV infusion” NCT07510594 ↗ “Cisplatin, carboplatin, nedaplatin and other platinum drugs” NCT05624099 ↗ “Platinum (carboplatin AUC 5 or cisplatin 75 mg/m²) on day 1” NCT07546383 ↗ “Pemetrexed/Cisplatin or Carboplatin Pemetrexed maintenance” NCT03353675 ↗ “cisplatin or carboplatin plus pemetrexed for adenocarcinoma” NCT05583188 ↗ “Cisplatin 25 mg/m2 once per week for a total of 5-6 cycles.” NCT06031597 ↗ “cisplatin, vindesine, ifosfamide, dacarbacine, doxorubicine” NCT03042429 ↗ “Cisplatin will be administered concurrently with radiation.” NCT05307939 ↗ “Cisplatin，60-75mg/m2 IV every 3 weeks (Q3W)，Other Name: DDP” NCT05833971 ↗ “Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.” NCT06091943 ↗ “3 cycles of paclitaxel 175mg/m2 and cisplatin 80mg/m2 q3w.” NCT00959387 ↗ “cisplatin injection (75 mg/m2, administered on Day 1, Q3W)” NCT07554846 ↗ “Platinum (carboplatin AUC 5, D1 or cisplatin 75 mg/m2, D1)” NCT06969027 ↗ “carboplatin AUC 5 / cisplatin 75mg/m2+ pemetrexed 500mg/m2” NCT06652048 ↗ “Cisplatin, Carboplatin, Docetaxel, Paclitaxel, Pemetrexed” NCT02064491 ↗ “Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy” NCT05742607 ↗ “Cisplatin and gemcitabine cisplatin or CAPOX or mFOLFOX6.” NCT06333314 ↗ “Adjuvant chemotherapy (5FU and cisplatin) after resection” NCT01088581 ↗ “Cisplatin(60-80 mg/m2 intravenous infusion on Day 1, Q3W)” NCT07233850 ↗ “Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3” NCT01664975 ↗ “GDP (gemcitabine, cisplatin, dexamethasone) chemotherapy” NCT02276248 ↗ “Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)” NCT00215514 ↗ “Docetaxel 60 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks” NCT01282151 ↗ “docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day” NCT02290145 ↗ “All patients received IV cisplatin 75 mg/m(2) on day 1.” PMID 27411683 ↗ Jul 2016 “Cisplatin will be administered by IV infusion on Day 1.” NCT05852717 ↗ “cisplatin 70 mg/m2, avoiding light, intravenous drip d2” NCT06652022 ↗ “modified gemcitabine-cisplatin neoadjuvant chemotherapy” NCT04588168 ↗ “Weekly nab-paclitaxel and cisplatin during radiotherapy” NCT07609121 ↗ “Cisplatin/carboplatin + pemetrexed (non-squamous NSCLC)” NCT06939127 ↗ “Cisplatin of 40mg/m2 will be the most preferred regime.” NCT04772001 ↗ “Platinum based chemotherapies (Carboplatin, Cisplatin)” NCT02299999 ↗ “combined Pemetrexed (D1)+cisplatin (D1-3) chemotherapy” NCT01951469 ↗ “docetaxel plus cisplatin were used weekly in both arms” NCT01937208 ↗ “Cisplatin (C): 90 mg/m2 over 6 hours in 1000 ml/m2 NS” NCT01858922 ↗ “cisplatin 80 mg/m² IV are given on Day 1 of each cycle” NCT03581786 ↗ “cisplatin 75mg/m2 d1 Q3W,paclitaxel 100mg/m2 d1，d8，d15” NCT06208033 ↗ “Name/Substance: Cisplatin Formulation: Powder (30 mg)” NCT01434394 ↗ “paclitaxel+cisplatin/carboplatin ± bevacizumab+QL1706” NCT07035808 ↗ “Pemetrexed (500 mg/m\^2) plus cisplatin (75 mg/m\^2)” NCT07376382 ↗ “cisplatin 75mg per square meter of body-surface area” NCT03734952 ↗ “Cisplatin 50 mg/m2 D1, D8, D29, and D36; IV infusion” NCT03945227 ↗ “Cisplatin 25mg/m2 D1-3 of each 21-day cycle IV drip;” NCT05760053 ↗ “Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.” NCT05343325 ↗ “Cisplatin (75 mg/m\^2 intravenously \[IV\]) on Day 1” NCT02000531 ↗ “cisplatin or alternatively Carboplatin (AUC 5-6 D1)” NCT07055581 ↗ “cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5” NCT00910117 ↗ “cisplatin 75 mg/m2 as IV over approximately 2 hours” NCT02649829 ↗ “cisplatin: 75mg/m2, vgtt，d1，q3w, for up to 6 cycles” NCT05673577 ↗ “Weekly cisplatin 40 mg/m2 for a maximum of 5 cycles” NCT04583254 ↗ “with 75mg/m2 of cisplatin and 200mg of tislelizumab” NCT06258811 ↗ “cisplatin 20mg/m2 intravenously on days 1 through 4” NCT06255795 ↗ “Carboplatin AUC=5 or Cisplatin 75-80 mg/m² on Day 1” NCT07358676 ↗ “Cisplatin: 60 mg/m², intravenous infusion on Day 1” NCT07706985 ↗ “the association of Gemcitabine and Cisplatin (GC).” NCT03324282 ↗ “rituximab + dexamethasone + cytarabine + cisplatin” NCT02055924 ↗ “Cisplatin: 25 mg/m2 in day 1, day 2 and day 3, Q3W” NCT04151810 ↗ “Cisplatin, 50-75 mg/m², D2, intravenous drip, Q3W.” NCT07155122 ↗ “Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle” NCT03117335 ↗ “Pemetrexed, cisplatin, carboplatin or gemcitibine” NCT03057106 ↗ “Cisplatin: 60mg/m², Day 1, IV (21 days per cycle)” NCT06848439 ↗ “Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion” NCT01805557 ↗ “Docetaxel. Cisplatin, 5-fluoruracil, Radiotherapy” NCT01086826 ↗ “Cisplatin 75 mg/m^2 IV Q3W on Day 1 of each cycle” NCT04624204 ↗ “GP: gemcitabine 1g/m2 D1, 8 Cisplatin 80 mg/m2 d1” NCT05520814 ↗ “Cisplatin 25 mg IV on Day 1 and 8, every 3 weeks” NCT04308174 ↗ “cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31” NCT01843049 ↗ “Drug: Cisplatin/Carboplatin Intravenous Infusion” NCT05179317 ↗ “plus cisplatin(25mg/m\^2, iv, Q3W, Day1and Day8)” NCT05781958 ↗ “Cisplatin, Carboplatin, Flourouracil, Etoposide” NCT01525927 ↗ “cisplatin-gemcitabine or carboplatin-paclitaxel” NCT00404703 ↗ “TPF ( docetaxel, cisplatin and 5-fluorouracil )” NCT02944708 ↗ “Cisplatin; Carboplatin; Pemetrexed; Paclitaxel;” NCT07672223 ↗ “Cisplatin given at 75mg/m2 or Carboplatin AUC=5” NCT00112346 ↗ “Cisplatin: 80mg/m2, intravenous infusion for 4h” NCT06241599 ↗ “Cisplatin: 75mg/m\^2 Nab-paclitaxel: 260mg/m\^2” NCT07147426 ↗ “paclitaxel+carboplatin or pemetrexed+cisplatin” NCT04255836 ↗ “Carboplatin or cisplatin will be administered.” NCT07669779 ↗ “Drug: Cisplatin administered as an IV infusion” NCT05765032 ↗ “Cisplatin 25 mg/m\^2 on Days 4, 11, 18, and 25” NCT05497739 ↗ “Cisplatin 100mg/m2 every 3 weeks for 2 cycles” NCT06092957 ↗ “carbplatin, paclitaxel, pemetrexed, cisplatin” NCT05407675 ↗ “Cisplatin 100mg/m2 every 3 weeks for 2 cycles” NCT07328841 ↗ “* Cisplatin 25 mg/m² over 1 hour at D1 and D8” NCT02591030 ↗ “D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr” NCT00313872 ↗ “* Cisplatin: 60-75mg/m2, intravenous infusion” NCT05214222 ↗ “Carboplatin or Cisplatin intravenous infusion” NCT04420884 ↗ “Cisplatin 20 mg/m2/day IV x 5 days (D1 to D5)” NCT05705687 ↗ “HS-20117 + cisplatin/carboplatin + pemetrexed” NCT06621563 ↗ “Cisplatin 60-75 mg/m² intravenously on Day 1” NCT07446335 ↗ “Cisplatin: 75 mg/m2 IV over 30-60 min; Day 1” NCT04711824 ↗ “ECX (epirubicin, Cisplatin and Capecitabine)” NCT00113581 ↗ “Cisplatin\* 10 mg/m, Continuous infusion 1-4” NCT00113919 ↗ “Weekly cisplatin 40 mg/m2 or PD-1 inhibitors” NCT06641635 ↗ “carboplatin (5U/AUC) or cisplatin ( 75mg/m2)” NCT04094909 ↗ “cisplatin: 75mg/m2, i.v., 1 hour, once daily” NCT00765011 ↗ “cisplatin and vinorelbine based chemotherapy” NCT01118676 ↗ “Cisplatin(1000mg/m2, iv, Q3W, Day1 and Day8)” NCT06013943 ↗ “Cisplatin 75-80mg/m2 or carboplatin AUC = 5” NCT04733820 ↗ “TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²)” NCT05062005 ↗ “Experimental group:docetaxel,cisplatin,5-FU” NCT03196869 ↗ “E10A combined with Cisplatin and Paclitaxel” NCT00634595 ↗ “TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²)” NCT05860868 ↗ “Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles” NCT00883480 ↗ “cisplatin 60mg/m2 on day 1, need hydration” NCT01558947 ↗ “Cisplatin 50 mg/m2 IV infusion - days 1, 2” NCT01726374 ↗ “Cisplatin 50mg/m2, on day 1, every 3 weeks” NCT07135544 ↗ “* pemetrexed with cisplatin or carboplatin” NCT02178397 ↗ “Cisplatin 100 mg/m2 1 hour iv infusion d1” NCT00030771 ↗ “Cisplatin or Carboplatin With Gemcitabine” NCT01648023 ↗ “Cisplatin 30 mg/m² days 1, 8, 15, 22, 29.” NCT01372202 ↗ “Chemotherapy: Cisplatin and 5fluorouracil” NCT02556762 ↗ “Cisplatin: 20mg/m\^2, daily IV, days 1-4” NCT00673361 ↗ “Drug: gemcitabine, vincristine,cisplatin” NCT01192633 ↗ “1. Camrelizumab + Cisplatin + Paclitaxel” NCT07251062 ↗ “Docetaxel 25mg/m2 + Cisplatin 25mg/m2 QW” NCT05481775 ↗ “Subjects will receive Cisplatin plus 5FU” NCT00460265 ↗ “cisplatin 75mg/m2, d1, iv, q3w 2 cycles;” NCT06420908 ↗ “cisplatin: 75 mg/m2 day 1, every 3 weeks” NCT01211275 ↗ “Drug: Cisplatin 4-6 cycles every 3 weeks” NCT04449861 ↗ “cisplatin 75mg/m2 IV day 1 every 21 days” NCT01154140 ↗ “concomitant weekly intravenous Cisplatin” NCT03246750 ↗ “Cisplatin: 75 mg/m2 IV d1,Q3W ,2 cycles” NCT05904015 ↗ “3. PARP1, BRCA1: Cisplatin and Olaparib” NCT02101385 ↗ “Cisplatin 75 mg/m\^2 by IV infusion Q3W” NCT06475755 ↗ “docetaxel 36mg/m2 and cisplatin 75mg/m2” NCT00172380 ↗ “Carboplatin or Cisplatin+5-Fluorouracil” NCT02327078 ↗ “- Epirubicin + Cisplatin + Capecitabine” NCT00718354 ↗ “cisplatin 75 mg/m2 Paclitaxel 175 mg/m2” NCT01917695 ↗ “4. cisplatin : 7mg/m2 D1-4, intravenous” NCT04065308 ↗ “CisPlatin \[75 mg/m2, day 1 or day 2\]” NCT01248299 ↗ “Drug: Cisplatin, 60mg/m2, Q3W, C1C2C3.” NCT07645846 ↗ “cisplatin at 25mg/m\^2/day CI Days 1-4” NCT03391466 ↗ “cisplatin at 25 mg/m2 from days 1 to 3” NCT06811844 ↗ “Administration of cisplatin at 75mg/m²” NCT01376752 ↗ “Docetaxel and Cisplatin: IV infusion.” NCT01283217 ↗ “and Dacarbazine, Lomustine, Cisplatin” NCT05898451 ↗ “docetaxel, cisplatin and capecitabine” NCT02915965 ↗ “Cisplatin injection: intravenous drip” NCT05416775 ↗ “Cisplatin (60-80mg/m2) or Carboplatin” NCT03989336 ↗ “Paclitaxel + cisplatin or carboplatin” NCT07627620 ↗ “Standard chemotherapy: Cisplatin+5-FU” NCT04146402 ↗ “Paclitaxel, ifosfamide, and cisplatin” NCT02817958 ↗ “Cisplatin, 70 mg/m2 IV over 1hr, Day2” NCT04047693 ↗ “Pemetrexed, carboplatin or cisplatin” NCT02906150 ↗ “cisplatin (50 mg/m2 day1, 8, 29, 36)” NCT01211002 ↗ “Cisplatin: 70 mg/m², day 2, i.v., q3” NCT01374789 ↗ “cisplatin, 75-80mg/m2, q3w, 3 cycles” NCT06878222 ↗ “Cisplatin: IV, 75 mg/m2, Day1-3, Q3W” NCT05979818 ↗ “Dexamethasone, Cytarabine, Cisplatin” NCT01453504 ↗ “Cisplatin at a dose of 75 mg/m\^2 IV” NCT06899126 ↗ “* Cisplatin - Gemcitabine (Gem/Cis)” NCT06290687 ↗ “cisplatin/carboplatin and etoposide” NCT06306560 ↗ “Chlorambucil, Cisplatin, Cladribine” NCT02788201 ↗ “Cisplatin: 25 mg/m2 d1-3, i.v. Q3W.” NCT06041724 ↗ “cisplatin 75mg/m2 IV on d1 and d22” NCT03558035 ↗ “Cisplatin 75 mg/m2 IV Q3W on Day 1” NCT05745350 ↗ “in addition to cisplatin treatment” NCT00925743 ↗ “cisplatin 25 mg/m2, i.v. d1-d3,q3w” NCT05738434 ↗ “Cisplatin:25 mg/m2, iv, Q3W, D1,D8” NCT05820906 ↗ “Cisplatin 120 mg/m² intravenously” NCT07142863 ↗ “cisplatin and irinotecan given IV” NCT00381706 ↗ “cisplatin 25 mg/m2 iv on days 3-5” NCT02560441 ↗ “Cisplatin (Platinol, Platinol-AQ)” NCT00659269 ↗ “cisplatin 75 mg/m² every 3 weeks” NCT05255302 ↗ “cisplatin 60 mg/m2 i.v. on day 1” NCT00301548 ↗ “CapsuleX Combined with Cisplatin” NCT07495384 ↗ “Cisplatin: 25 mg/m2，iv，d1、d8，q3w” NCT07152769 ↗ “Cisplatin (75 mg/m² IV on Day 1)” NCT06554535 ↗ “Cisplatin(P) 25mg/m2,IV,Day 1-3” NCT03706287 ↗ “or cisplatin, 75 mg/m2, IV, q3w” NCT05055583 ↗ “Cisplatin(P) 25mg/m2,IV,Day 1-3” NCT03201146 ↗ “Cisplatin:75 mg/m2, iv., d1,q3w” NCT05476380 ↗ “Cisplatin: 25mg/m2, Day1-3, Q3W” NCT06081582 ↗ “combined cisplatin 25mg/m2，D1-3” NCT02621333 ↗ “cisplatin (75 mg/m²) IV d1, q3w” NCT07286240 ↗ “Cisplatin+doxorubicin (5 pat.).” NCT01379482 ↗ “Cisplatin(P): 75 mg/m2 on day 1” NCT02812641 ↗ “Cisplatin (25mg/m2 IV D1-3 Q3W)” NCT04602013 ↗ “Cisplatin: 75mg / m2, 1-3 days” NCT05243355 ↗ “IP cisplatin 100 mg/m2 (day 2)” NCT06902467 ↗ “Cisplatin: 75mg/m2, d1-3, q3w” NCT07028918 ↗ “Cisplatin: 75 mg/m², d1, Q3W;” NCT07290010 ↗ “Cisplatin 100 mg/ m2 IV on D1” NCT05966233 ↗ “Cisplatin: 100 mg/m2, day 15” NCT05926492 ↗ “Cisplatin, 75mg/m2 D1 IV Q3W” NCT07138755 ↗ “Cisplatin (CDDP) (Platinol®)” NCT02128230 ↗ “CISPLATIN: 70 mg/m² on day 2” NCT02818725 ↗ “Cisplatin 25mg/m2, ivg, d1-4” NCT03105596 ↗ “cisplatin 100 mg/m2 on Day 1” NCT01626664 ↗ “Cisplatin 25 mg/m2 on day 1.” NCT06903273 ↗ “cisplatin 10 mg/m2 days 1-4” NCT00670631 ↗ “4. Cisplatin 70 mg/m2 IV D1” NCT03549715 ↗ “Cisplatin 100mg/m2 D1, I.V.” NCT04736914 ↗ “cisplatin 75mg/m2，iv，d1，Q3W” NCT06463834 ↗ “cisplatin 75 mg/m2, iv day1” NCT03769935 ↗ “cisplatin 30 mg/m2 (90 min)” NCT00785421 ↗ “cisplatin/radiation therapy” NCT00463515 ↗ “Drug: cisplatin（DDP） weekly” NCT05277688 ↗ “Cisplatin 100mg/m2 D1, I.V.” NCT06255704 ↗ “- Cisplatin 75 (-100) mg/m²” NCT02128243 ↗ “Cisplatin: 75 mg/m² D1, Q3W” NCT07358689 ↗ “cisplatin(50mg/m2.d, d3-d6)” NCT06933394 ↗ “Cisplatin 40 mg/m2 iv day 1” NCT05527782 ↗ “cisplatin (75mg/m2 D1, q3w)” NCT06908382 ↗ “Cisplatin (40 mg/m², day 1)” NCT06207981 ↗ “Platinol-AQ(R) (cisplatin)” NCT00602667 ↗ “Cisplatin 120 mg/m2/course” NCT04351308 ↗ “Cisplatin (75 mg/m2 day 1)” NCT01133678 ↗ “Cisplatin (Day 1: 75mg/m2)” NCT02947113 ↗ “cisplatin 75-80mg/m2 day 1” NCT06479473 ↗ “cisplatin (12mg/m2,day1-5)” NCT00915850 ↗ “cisplatin 25mg/m2, iv d1-3” NCT06062641 ↗ “cisplatin 80 mg/m\^2 on D1” NCT00820755 ↗ “TP (cisplatin + docetaxel)” NCT06895369 ↗ “Cisplatin and Gemcitabine” NCT03930498 ↗ “Cisplatin (P):75mg d1 q3w” NCT01669707 ↗ “DDP(cisplatin) 75mg/m2 d2” NCT03251313 ↗ “cisplatin 50 mg/m² IV Q2W” NCT06145308 ↗ “Cisplatin 30mg/m² QW (D1)” NCT07139041 ↗ “cisplatin 25mg/m2 iv D1-4” NCT03373019 ↗ “Gemcitabine and cisplatin” NCT05116891 ↗ “Cisplatin, 75mg/m2，day 1;” NCT06978153 ↗ “Cisplatin 14mg/m2 day 1-5” NCT00190528 ↗ “cisplatin 30mg/m2, ivgtt” NCT06402708 ↗ “cisplatin 75 mg/m2 i.v.” NCT07715396 ↗ “cisplatin, Fluorouracil” NCT00992199 ↗ “cisplatin: 75mg/m2, Q3W” NCT06709417 ↗ “intralesional Cisplatin” NCT06715592 ↗ “Cisplatin 20mg/m2 D2-D4” NCT04389177 ↗ “cisplatin (25 mg/m², IV” NCT07638501 ↗ “Cisplatin 25mg/m2, d1-3” NCT04134247 ↗ “Cisplatin 40mg/m2, qw×5” NCT07400536 ↗ “cisplatin 75 mg/m2 i.v.” NCT01262183 ↗ “Cisplatin 75 mg/m² i.v.” NCT01368848 ↗ “Cisplatinum 100 mg / m²” NCT02983097 ↗ “cisplatin 75mg/m2 iv d1” NCT02194556 ↗ “SP(S-1 with cisplatin)” NCT01283204 ↗ “Pemetrexed + Cisplatin” NCT00482014 ↗ “Cisplatin + pemetrexed” NCT02659059 ↗ “Drug: Cisplatin 75 mg” NCT06437977 ↗ “Pemetrexed, Cisplatin” NCT04322890 ↗ “cisplatin 100mg/m2 D1” NCT05244642 ↗ “cisplatin IV on day 1” NCT00349492 ↗ “Cisplatin/carboplatin” NCT04428333 ↗ “Cisplatin (Platinol®)” NCT02983045 ↗ “Cisplatin 25mg/m2 D5” NCT02431403 ↗ “cisplatin 75mg/m2 d1” NCT02103257 ↗ “Cisplatin (75 mg/m²)” NCT07416058 ↗ “Cisplatin (Platinol)” NCT03415854 ↗ “Cisplatin 60mg/M2 D1” NCT00595972 ↗ “Cisplatin (Platinol)” NCT03138720 ↗ “cisplatin, 75 mg/m2” NCT06241807 ↗ “cisplatin (75mg/m²)” NCT05430906 ↗ “cisplatin 75 mg/m2” NCT07472153 ↗ “Cisplatin: 75mg/m2” NCT07388095 ↗ “Cisplatin 80mg/m2” NCT05340491 ↗ “Cisplatin：60mg/m2” NCT02862587 ↗ “Drug: Cisplatin” NCT03383094 ↗ “Drug: Cisplatin” NCT07407452 ↗ “Drug: Cisplatin” NCT06241235 ↗ “Drug: Cisplatin” NCT02885974 ↗ “Drug: Cisplatin” NCT06510465 ↗ “Cisplatin 50 mg” NCT05173272 ↗ “Drug: Cisplatin” NCT03872947 ↗ “* cisplatin” NCT03070366 ↗ “Cisplatin” NCT01097252 ↗ “Cisplatin” NCT03079427 ↗ “Cisplatin” NCT00304278 ↗ “Cisplatin” NCT05476380 ↗ “Cisplatin” NCT03351842 ↗ “cisplatin” NCT05880082 ↗ “Cisplatin” NCT07371611 ↗ “CISPLATIN” NCT05266846 ↗ “Cisplatin” NCT04851834 ↗ “Cisplatin” NCT03351842 ↗ “cisplatin” NCT02363400 ↗ “Cisplatin” NCT03377400 ↗ “Cisplatin” NCT03837873 ↗ “Cisplatin” NCT04769076 ↗ “Cisplatin” NCT01703910 ↗ “Cisplatin” NCT04054362 ↗ “Cisplatin” NCT00734877 ↗ |
| Known as | Abiplatin | “Abiplatin” NCT04106362 ↗ |
| Known as | Briplatin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00209716 ↗ |
| Known as | CACP | “CACP” NCT00064259 ↗ |
| Known as | CDDP | “METHODS: Forty (40) chemotherapy-naive patients with unresectable LAPC were randomly assigned (1:1) to either continuous fluorouracil (5-FU) 200 mg/m(2)/day (protracted IV) and...” PMID 21943032 ↗ Sep 201143“The treatment regimen was as follows: oral administration of sorafenib (400 mg twice daily for 28 days) combined with HAIC using CDDP (14-20 mg/m(2), on days 1 and 8) and 5-FU...” PMID 26734580 ↗ Oct 2015 “Cisplatin (cis-diammine dichloroplatinum (II), CDDP) is an inorganic platinum-based chemotherapeutic agent that is widely used in treatment of various solid malignancies as...” NCT05640817 ↗ “By far, the most common drug evaluated in HIPEC for EOC is Cisplatin. Cisplatin (CDDP) is a heavy metal complex containing a central atom of platinum surrounded by two chloride...” NCT03540017 ↗ “With the routine addition of systemic Cisplatin (CDDP) chemotherapy to local regional radiation, mortality from advanced cervical cancer in the United States is expected to...” NCT00257816 ↗ “Patients receive chemotherapy consisting of cisplatin (CDDP) via rapid intravenous infusion on day 1 followed by fluorouracil (5-FU) via 96-hour continuous infusion” NCT00002984 ↗ “patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1” NCT01670890 ↗ “The aim of this trial was to evaluate the safety and feasibility of moderate hypofractionated radiotherapy (HYP-RT) with concomitant cisplatin (CDDP).” PMID 30352576 ↗ Oct 2018 “concurrent FU plus cisplatin (CDDP), but did not significantly impact disease-free survival (DFS) or overall survival (OS) for anal canal carcinoma.” PMID 23150707 ↗ Nov 2012 “A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma” PMID 18417462 ↗ Apr 2008 “Carboplatin, CBDCA, NSC-241240; or CAP: Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; Cisplatin, CDDP, NSC-119875.” NCT00002477 ↗ “Chemotherapy consists of cisplatin (CDDP) by bolus IV infusion over 30 minutes on day 1 and again on day 29.” NCT00003118 ↗ “conventional doxorubicin (DOX) IV over 4 hours on days 1-3 and cisplatin (CDDP) IV continuously on day 1” NCT00002539 ↗ “Arm II: 2-Drug Combination Chemotherapy. Doxorubicin, DOX, NSC-123127; Cisplatin, CDDP, NSC-119875.” NCT00002493 ↗ “CVP: Cyclophosphamide, CTX, NSC-26271; Etoposide, VP-16, NSC-141540; Cisplatin, CDDP, NSC-119875.” NCT00002488 ↗ “The use of intraperitoneal cisplatin (CDDP) is associated with a risk of acute kidney injury.” PMID 34350529 ↗ Aug 2021 “oxaliplatin (OXA) 120 mg/sm, cisplatin (CDDP) 10.5 mg/sm and doxorubicin (DXR) 2.1 mg/sm.” PMID 34070561 ↗ May 2021 “plus Cisplatin, CDDP, NSC-119875; Fluorouracil, 5-FU, NSC-19893.” NCT00002631 ↗ “Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1” NCT01640782 ↗ “Cisplatin, CDDP, NSC-119875; followed by chest irradiation” NCT00001499 ↗ “A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)” NCT01096199 ↗ “cisplatin (cis-diamminedichloroplatinum(II) (CDDP))” NCT07495098 ↗ “neoadjuvant cisplatin/fluorouracil (CDDP/5-FU)” NCT00002783 ↗ “cisplatin (CDDP) plus 5-fluorouracil (5-FU)” NCT02969473 ↗ “cisplatin (CDDP) IV over 30-60 minutes” NCT00002596 ↗ “mitomycin C (MMC) and cisplatin (CDDP)” PMID 19643599 ↗ Jul 2009 “Cisplatin (CDDP) 75mg/m2 IV D1” NCT03890185 ↗ “Cisplatin (CDDP) 25 mg/mq i.v” NCT06341764 ↗ “Cisplatin, CDDP, NSC-119875.” NCT00002568 ↗ “Cisplatin, CDDP, NSC-119875” NCT00002496 ↗ “CBP501, CDDP plus Nivolumab” NCT03113188 ↗ “CDDP Cisplatin, NSC-119875” NCT00002565 ↗ “Cisplatin (CDDP)” NCT06900647 ↗ “cisplatin (CDDP)” NCT00003029 ↗ “Cisplatin (CDDP)” NCT00455572 ↗ “CDDP Cisplatin” NCT00002711 ↗ |
| Known as | Cis | “This study will use imaging to look at tumor response to combination chemotherapy of gemcitabine (Gem) and cisplatin (Cis) or gemcitabine and carboplatin (Carbo) in non small...” NCT00599755 ↗6“Planned chemotherapy consisted of cisplatin (CIS) 50 mg/m2 days 1, 8 and vinorelbine (VIN) 25 mg/m2 days 1, 8, 15, 22 for four cycles.” PMID 15713522 ↗ Mar 2005 “Cisplatin (Cis) was administered intravenously starting at 70 mg/m\^2 (1-4 hours) once every 3 weeks on Day 1 of each 21-day cycle.” NCT02393248 ↗ “gemcitabine (Gem) with vinorelbine (Vin), etoposide (Eto), cisplatin (Cis), or carboplatin (Car).” PMID 22031232 ↗ Jan 2012 “Cisplatin (Cis) will be administered at a dose of 75 mg/m\^2 as intravenous infusion on Day 1.” NCT00842712 ↗ “Cisplatin (CIS) is a platinum derivate used in the treatment in several epithelial tumours.” NCT04402073 ↗ “cisplatin (Cis) chemotherapy” NCT05738057 ↗ |
| Known as | cis-diammine dichloroplatinum (II) | “Cisplatin (cis-diammine dichloroplatinum (II), CDDP) is an inorganic platinum-based chemotherapeutic agent that is widely used in treatment of various solid malignancies as...” NCT05640817 ↗1“cisplatin (cis-diamminedichloroplatinum(II) (CDDP))” NCT07495098 ↗ |
| Known as | cis-diamminedichloroplatinum | “Cisplatin is an alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.” NCT06783140 ↗ |
| Known as | cis-dichlorodiamineplatin | “Cisplatin, aka cis-dichlorodiamineplatin, is a platinum-containing anticancer drug” NCT05039606 ↗ |
| Known as | cis-dichlorodiammineplatinums II | “Cisplatin (cis-dichlorodiammineplatinums II) is a first generation platinum compound.” NCT04789941 ↗ |
| Known as | cis-platin: L01XA01 | “cis-platin: L01XA01” NCT01614132 ↗ |
| Known as | cis-platinum | “The purpose of this study is to find out what the response is and the side effects are with chemotherapy using a combination of drugs called D.T. PACE (Dexamethasone,...” NCT00107614 ↗47“pemetrexed 500 mg/m2 plus platinum [carboplatin, area under curve (AUC) of 5, or cis-platinum 75 mg/m2] for non-squamous NSCLC” PMID 39756446 ↗ Jan 2025 “A FP regimen with 5-Fu 850mg/m\^2 d1-4 + cis-platinum 850mg/m\^2 d1-4 was used, on D1, D22 and D43 infused intravenously.” NCT05469061 ↗ “cis-platinum one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1” NCT04590625 ↗ “TP:albumin-bound paclitaxel 110-130mg/m2,d1,d8;cis-platinum 60-75mg/m2,d1 Q3W” NCT06478355 ↗ “DDP(cis-platinum),75mg/m2,ivgtt,\>1h,d1; or DDP25 mg/m2,ivgtt,\>1h,d1-3.” NCT02520219 ↗ “cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5” NCT00970385 ↗ “chemotherapy (paclitaxel/cisplatinum) and brachytherapy” NCT03243825 ↗ “docetaxel, cisplatinum (cisplatin) and 5-fluorouracil” NCT00400205 ↗ “Drug: Cisplatinum Drug: Paclitaxel Drug: Sintilimab” NCT05476965 ↗ “Adriamycin + Cisplatinum and Ifosfamide” NCT00691236 ↗ “cisplatinum \[25 mg/m2/day IV, D1-4\]” NCT04378647 ↗ “Cisplatinum: 120mg/m2 (3 cycles)” NCT01459484 ↗ “Gemcitabine / cisplatinum” NCT01726582 ↗ “Cis-platinum 75 mg/m2 d 1” NCT01181401 ↗ “Drug: cis Platinum” NCT03141359 ↗ |
| Known as | cisplatin (associated to radiotherapy) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01216020 ↗ |
| Known as | Cisplatin (C) | “Cisplatin (C)” NCT01858922 ↗ |
| Known as | Cisplatin (CDDP) (Platinol) | “Cisplatin (CDDP) (Platinol®)” NCT02128230 ↗ |
| Known as | Cisplatin (Platinol) | “Cisplatin (Platinol®)” NCT02983045 ↗3“Cisplatin (Platinol)” NCT03415854 ↗ “Cisplatin (Platinol)” NCT03138720 ↗ “Cisplatin (Platinol)” NCT04989218 ↗ |
| Known as | Cisplatin (Platinol, Platinol-AQ) | “Cisplatin (Platinol, Platinol-AQ)” NCT00659269 ↗ |
| Known as | Cisplatin - Cispulan | “Cisplatin - Cispulan” NCT01096745 ↗1“Cisplatin ； Cispulan” NCT01834963 ↗ |
| Known as | cisplatin / cisplatinum | “cisplatin / cisplatinum” NCT04268121 ↗ |
| Known as | Cisplatin 0.5mg/ml solution medac (Cisplatin) | “Cisplatin 0.5mg/ml solution medac (Cisplatin)” NCT01320254 ↗ |
| Known as | Cisplatin for Injection | “Cisplatin for injection binds to DNA, interfering with DNA replication and transcription processes, Thus inhibiting tumor cell proliferation” NCT06897579 ↗1“Cisplatin for Injection / Carboplatin Injection” NCT04568304 ↗ |
| Known as | Cisplatin Injection | “Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle for the first four...” NCT06514027 ↗1“This study is to analyze the safety and efficacy of immunotherapy Triprilumab Injection combined with Gemcitabine Injection plus Cisplatin Injection in patients with advanced...” NCT04413734 ↗ |
| Known as | cisplatin liposomal | “Patients receive cisplatin liposomal (SPI-77) IV over a minimum of 4 hours on day 1.” NCT00004083 ↗ |
| Known as | Cisplatin, PLATINOL-AQ | “Cisplatin, PLATINOL®-AQ” NCT00942838 ↗ |
| Known as | Cisplatin: CDDP | “Cisplatin: CDDP” NCT00546130 ↗ |
| Known as | Cisplatin: Cisplatin for injection | “Cisplatin: Cisplatin for injection” NCT02223611 ↗ |
| Known as | cisplatine | “Cisplatine 25 mg/m² in 1 hour IV in 1000 ml NaCl 0,9 % then 500 ml NaCl 0,9 %” NCT07128290 ↗6“CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.” NCT02014831 ↗ “Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1” NCT00535275 ↗ “R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)” NCT02858258 ↗ “1 cycle of Etoposide Cisplatine (EP) chemotherapy.” NCT05529251 ↗ |
| Known as | Cisplatine Teva | “PITHAC: Cisplatin (Cisplatine Teva®) at a dose between 7.5 and 70 mg/m2 of body surface at a temperature of 39±1°C” NCT06281860 ↗ |
| Known as | Cisplatino | “* cis-Platino100 mg/m2, day 2 (if ≥70 years 75 mg/m2)” NCT02371161 ↗ |
| Known as | cisplatin（DDP） | “cisplatin（DDP）” NCT03840421 ↗ |
| Known as | cisplatyl | “cisplatin (cisplatyl)” NCT00251888 ↗ |
| Known as | DDP | “Lipusu (T) + Cisplatin (DDP) program: T 135mg/m2 ivgtt, d1, 3week\*2cycles; DDP 75mg/m2 ivgtt, d2, 3week\*2cycles;” NCT05775419 ↗10“Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation.” NCT05622474 ↗ “concurrent chemotherapy with cisplatin（DDP） weekly(40mg/m2),begin with radiation” NCT01999933 ↗ “Concurrent chemotherapy: Cisplatin monotherapy: DDP 75 mg/m2 for 3 days, q3w.” NCT05872724 ↗ “DDP(cis-platinum),75mg/m2,ivgtt,\>1h,d1; or DDP25 mg/m2,ivgtt,\>1h,d1-3.” NCT02520219 ↗ “Cisplatin (DDP): 80 mg/m² on Day 1-3; every 3 weeks for 3 cycles” NCT06605131 ↗ “Cisplatin，60-75mg/m2 IV every 3 weeks (Q3W)，Other Name: DDP” NCT05833971 ↗ “Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3” NCT01664975 ↗ “Drug: cisplatin（DDP） weekly” NCT05277688 ↗ “DDP(cisplatin) 75mg/m2 d2” NCT03251313 ↗ “Drug: Cisplatin (DDP)” NCT02512315 ↗ |
| Known as | HA132 | “Cisplatin micelle injection (HA132)” NCT05478785 ↗ |
| Known as | ILC | “Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung.” PMID 23255417 ↗ Dec 2012 |
| Known as | L01XA01 Cisplatin | “L01XA01 Cisplatin” NCT05738161 ↗ |
| Known as | LiPlaCis | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01861496 ↗ |
| Known as | NSC-119875 | “A Limited Access Phase II Trial of Weekly Topotecan (NSC #609699), Paclitaxel (NSC #673089), and Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent...” NCT00276796 ↗10“A Phase I Trial of Tailored Radiation Therapy With Concomitant Cetuximab (C225, NSC #714692) and Cisplatin (NSC #119875) in the Treatment of Patients With Cervical Cancer” NCT00104910 ↗ “Carboplatin, CBDCA, NSC-241240; or CAP: Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; Cisplatin, CDDP, NSC-119875.” NCT00002477 ↗ “Arm I: Intratumoral Chemotherapy. Cisplatin (NSC-119875) and Epinephrine in a bovine collagen gel, MP 5010, CDDP-e TI.” NCT00002659 ↗ “Arm II: 2-Drug Combination Chemotherapy. Doxorubicin, DOX, NSC-123127; Cisplatin, CDDP, NSC-119875.” NCT00002493 ↗ “CVP: Cyclophosphamide, CTX, NSC-26271; Etoposide, VP-16, NSC-141540; Cisplatin, CDDP, NSC-119875.” NCT00002488 ↗ “plus Cisplatin, CDDP, NSC-119875; Fluorouracil, 5-FU, NSC-19893.” NCT00002631 ↗ “Cisplatin, CDDP, NSC-119875; followed by chest irradiation” NCT00001499 ↗ “Cisplatin, CDDP, NSC-119875.” NCT00002568 ↗ “Cisplatin, CDDP, NSC-119875” NCT00002496 ↗ “CDDP Cisplatin, NSC-119875” NCT00002565 ↗ |
| Known as | PLAT | “Intra-arterial Cisplatin (PLAT)” NCT00304278 ↗ |
| Known as | Platinex (Cisplatin) | “Platinex (Cisplatin)” NCT00846508 ↗ |
| Known as | Platinol | “A Phase II Trial of Gemzar (Gemcitabine), Taxol (Paclitaxel), and Platinol (Cisplatin) (GTP) in Treatment of Advanced Transitional Cell Carcinoma of the Urothelium” NCT00310011 ↗ |
| Known as | Platinol (Cisplatin) | “Platinol (Cisplatin)” NCT05948462 ↗ |
| Known as | Platinol-AQ | “PLATINOL®-AQ (cisplatin injection) is a clear, colorless, sterile aqueous solution, each mL containing 1 mg cisplatin and 9 mg Sodium Chloride, USP.” NCT00942838 ↗1“Cisplatin (Platinol-AQ)” NCT00514540 ↗ |
| Known as | Platinol-AQ(R) (cisplatin) | “Platinol-AQ(R) (cisplatin)” NCT00602667 ↗ |
| Known as | Platiran | “Platiran” NCT00408694 ↗ |
| Known as | SPI-77 | “Patients receive cisplatin liposomal (SPI-77) IV over a minimum of 4 hours on day 1.” NCT00004083 ↗ |
| Known as | Stealth Liposomal Cisplatin | “A Phase II Pilot Study of SPI-77 (Stealth Liposomal Cisplatin) in Patients With Recurrent Platinum-Sensitive Ovarian Cancer” NCT00004083 ↗ |
| Action | Inhibit | “Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die.” NCT00002608 ↗ |
| Modality | Other / unclassified | “DNA damaging agent cisplatin concurrent with radiation therapy (RT)” NCT01445405 ↗ |
| Route | Other | “continuous hyperthermic peritoneal perfusion with cisplatin (CHPP)” NCT00001569 ↗ |